| Symbol | REGN |
|---|---|
| Name | REGENERON PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, New York, 10591-6707, United States |
| Telephone | +1 914 847-7000 |
| Fax | — |
| — | |
| Website | https://www.regeneron.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000872589 |
| Description | Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently. Additional info from NASDAQ: |
2026-07-07 20:05
Director RYAN ARTHUR F 🔴 sold 200 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $650.15 Transaction Date: Jul 02, 2026 | Filing ID: 000010
Read more
2026-07-06 11:00
(99% Neutral) REGENERON PHARMACEUTICALS, INC. (REGN) Reports Q3 2026 Financial Results
Read more
2026-07-02 21:46
📋 Arthur F. Ryan (Director) plans to sell 400 shares of Regeneron Pharmaceuticals, Inc. (at $624.72 each, total $250K) Filed: Jul 02, 2026 | ID: 000693
Read more
2026-06-25 20:05
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
Read more
2026-06-22 11:00
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Read more
2026-06-17 20:05
(99% Neutral) REGENERON PHARMACEUTICALS, INC. (REGN) Announces Regulatory Update
Read more
2026-06-11 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Read more
2026-06-10 19:00
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Read more
2026-06-04 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Read more
2026-05-28 14:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05232110 | Compassionate Use of Pozelimab | — | CD55-deficient Protein-losing Enteropathy | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06063746 | Compassionate Use of Vidutolimod | — | Refractory Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01714115 | Use of Eylea for the Treatment of an Optic Nerve Hemangioma | — | Retinal Hemangioma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06132191 | Expanded Access Use of Cemiplimab in Patients With Solid Tumors | — | Non-Small Cell Lung Cancer (NSCLC) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05164250 | Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Mul… | — | Multiple Myeloma | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00609544 | Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Su… | Phase2 | Chronic Kidney Disease | Withdrawn | — | — | ClinicalTrials.gov |
| NCT04617535 | Compassionate Use of REGN-COV2 for the Treatment of COVID-19 | — | COVID-19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06028594 | Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients W… | — | Paroxysmal Nocturnal Hemoglobinuria | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06500598 | Compassionate Use of Evinacumab | — | Pediatric Homozygous Familial Hypercholesterolemia (HoFH) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04776694 | Compassionate Use of Dupilumab | — | Type 2 Inflammatory Disorders | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06631677 | Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Media… | — | Food Allergy | Available | — | — | ClinicalTrials.gov |
| NCT06003881 | Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing E… | — | CD55-Deficient Protein-Losing Enteropathy | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07502716 | Compassionate Use of Ubamatamab | — | Renal Medullary Carcinoma (RMC) | Available | — | — | ClinicalTrials.gov |
| NCT07301450 | An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia … | — | Fibrodysplasia Ossificans Progressiva (FOP) | Temporarily_Not_Available | — | — | ClinicalTrials.gov |
| NCT05619367 | A Compassionate Use (CU) Program of Odronextamab | — | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | Available | — | — | ClinicalTrials.gov |
| NCT03576690 | R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebol… | — | Ebola Virus Disease | Available | — | — | ClinicalTrials.gov |
| NCT04710056 | Expanded Access to REGN4461 for Patients With Diseases Associated With Deficien… | — | Lipodystrophy | Available | — | — | ClinicalTrials.gov |
| NCT05202288 | Impact of Delay Between Administration of Inmazeb Administration and Vaccinatio… | Phase2 | Ebola Virus Disease | Not_Yet_Recruiting | 2027-01-01 | 2027-08-01 | ClinicalTrials.gov |
| NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and … | Phase1 | High-Grade Glioma (HGG) | Not_Yet_Recruiting | 2026-08-31 | 2034-08-17 | ClinicalTrials.gov |
| NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy… | Phase2 | Glioblastoma | Not_Yet_Recruiting | 2026-08-31 | 2032-08-31 | ClinicalTrials.gov |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | Phase1 | Ovarian Cancer | Not_Yet_Recruiting | 2026-08-01 | 2030-04-01 | ClinicalTrials.gov |
| NCT07433673 | Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advance… | Phase2 | Colon and Rectal Cancer | Recruiting | 2026-08-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06449313 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-… | Phase2 | Non-small Cell Lung Cancer Stage III | Recruiting | 2026-08-01 | 2032-09-01 | ClinicalTrials.gov |
| NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibri… | Phase3 | Atrial Fibrillation (AF) | Not_Yet_Recruiting | 2026-07-31 | 2029-12-10 | ClinicalTrials.gov |
| NCT07559513 | A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garet… | Phase3 | Fibrodysplasia Ossificans Progressiva (FOP) | Not_Yet_Recruiting | 2026-07-30 | 2029-12-21 | ClinicalTrials.gov |
| NCT07318610 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participa… | Phase3 | Peripheral Artery Disease (PAD) | Recruiting | 2026-07-30 | 2029-11-16 | ClinicalTrials.gov |
| NCT07685808 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity … | Phase2 | Overweight or Obesity | Not_Yet_Recruiting | 2026-07-29 | 2028-01-21 | ClinicalTrials.gov |
| NCT07675811 | A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in… | Phase3 | Allergic Conjunctivitis | Not_Yet_Recruiting | 2026-07-27 | 2028-06-30 | ClinicalTrials.gov |
| NCT07675824 | REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension | Phase1 | Primary Open Angle Glaucoma (POAG) | Not_Yet_Recruiting | 2026-07-23 | 2029-10-16 | ClinicalTrials.gov |
| NCT07609940 | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Ris… | Phase4 | Relapsed/Refractory Multiple Myeloma (RRMM) | Not_Yet_Recruiting | 2026-07-17 | 2028-12-06 | ClinicalTrials.gov |
| NCT07631637 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Assoc… | Phase2 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Not_Yet_Recruiting | 2026-07-15 | 2029-02-06 | ClinicalTrials.gov |
| NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prosta… | Phase1 | Prostate Cancer | Recruiting | 2026-07-07 | 2031-04-25 | ClinicalTrials.gov |
| NCT07650266 | A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma | Phase1 | Nasopharyngeal Carcinoma | Not_Yet_Recruiting | 2026-07-01 | 2030-07-01 | ClinicalTrials.gov |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People… | Phase2 | Bladder Urothelial Carcinoma | Not_Yet_Recruiting | 2026-07-01 | 2028-03-01 | ClinicalTrials.gov |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocell… | Phase1 | Hepatocellular Carcinoma | Not_Yet_Recruiting | 2026-07-01 | 2035-02-28 | ClinicalTrials.gov |
| NCT07224022 | Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer | Phase2 | Colon Cancer | Not_Yet_Recruiting | 2026-07-01 | 2029-11-30 | ClinicalTrials.gov |
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab … | Phase2 | Colorectal Cancer | Recruiting | 2026-07-01 | 2030-07-01 | ClinicalTrials.gov |
| NCT07587658 | This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Not_Yet_Recruiting | 2026-06-30 | 2028-07-30 | ClinicalTrials.gov |
| NCT07493304 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Par… | Phase3 | Venous Thromboembolism (VTE) | Recruiting | 2026-06-30 | 2031-07-08 | ClinicalTrials.gov |
| NCT07594093 | Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity | Phase1 | Overweight or Obesity | Recruiting | 2026-06-29 | 2027-02-22 | ClinicalTrials.gov |
| NCT07477704 | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult … | Phase2 | Hypercholesterolemia | Recruiting | 2026-06-17 | 2027-02-23 | ClinicalTrials.gov |
| NCT07154745 | A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adu… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 2026-06-11 | 2031-12-04 | ClinicalTrials.gov |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newl… | Phase2 | Multiple Myeloma (MM) | Withdrawn | 2026-06-05 | 2038-05-21 | ClinicalTrials.gov |
| NCT07450183 | Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD… | Phase2 | Lung Cancer (NSCLC) | Not_Yet_Recruiting | 2026-06-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07387198 | Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplim… | Phase2 | Merkel Cell Carcinoma, Stage I | Recruiting | 2026-05-29 | 2031-07-31 | ClinicalTrials.gov |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSM… | Phase1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Not_Yet_Recruiting | 2026-05-25 | 2030-09-20 | ClinicalTrials.gov |
| NCT07527923 | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adul… | Phase1 | Healthy Volunteer | Recruiting | 2026-05-22 | 2028-06-23 | ClinicalTrials.gov |
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients … | Phase2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Recruiting | 2026-05-22 | 2030-03-15 | ClinicalTrials.gov |
| NCT07393282 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smolder… | Phase3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | Recruiting | 2026-05-21 | 2033-07-27 | ClinicalTrials.gov |
| NCT07484230 | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab … | Phase3 | Chronic Rhinosinusitis With Nasal Polyps | Not_Yet_Recruiting | 2026-05-08 | 2028-10-10 | ClinicalTrials.gov |
| NCT07318597 | Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (… | Phase2 | Pulmonary Arterial Hypertension (PAH) | Recruiting | 2026-05-06 | 2028-09-17 | ClinicalTrials.gov |
| NCT06790602 | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcino… | Phase2 | Pancreatic Ductal Adenocarcinoma (mPDAC) | Recruiting | 2026-05-06 | 2029-12-01 | ClinicalTrials.gov |
| NCT07188896 | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plu… | Phase2 | Advanced Renal Cell Carcinoma (aRCC) | Recruiting | 2026-04-29 | 2030-11-30 | ClinicalTrials.gov |
| NCT07217535 | Rutgers University Study of the Genetics of Kidney Disease | — | Kidney Disease | Recruiting | 2026-04-23 | 2028-10-31 | ClinicalTrials.gov |
| NCT07058012 | A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or … | Phase2 | Colo-rectal Cancer | Recruiting | 2026-04-17 | 2029-06-01 | ClinicalTrials.gov |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemip… | Phase2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | 2026-04-14 | 2030-12-28 | ClinicalTrials.gov |
| NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibri… | Phase3 | Atrial Fibrillation (AF) | Recruiting | 2026-04-03 | 2029-06-26 | ClinicalTrials.gov |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable fo… | Phase1 | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting | 2026-03-26 | 2033-09-30 | ClinicalTrials.gov |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Re… | Phase1 | Recurrent Multiple Myeloma | Recruiting | 2026-03-24 | 2028-06-30 | ClinicalTrials.gov |
| NCT07142343 | A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years … | Phase4 | CHAPLE Disease | Recruiting | 2026-03-19 | 2030-02-12 | ClinicalTrials.gov |
| NCT07154290 | A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participan… | Phase2 | Advanced/Metastatic Non-Small Cell Lung Cancer | Recruiting | 2026-03-18 | 2030-06-24 | ClinicalTrials.gov |
| NCT07431086 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity … | Phase2 | Overweight or Obesity | Active_Not_Recruiting | 2026-03-16 | 2026-12-18 | ClinicalTrials.gov |
| NCT07220785 | Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With General… | Phase3 | Generalized Lipodystrophy | Recruiting | 2026-03-13 | 2028-09-08 | ClinicalTrials.gov |
| NCT07235917 | A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic … | Phase2 | Functional Hypothalamic Amenorrhea (FHA) | Recruiting | 2026-03-11 | 2027-12-08 | ClinicalTrials.gov |
| NCT07410117 | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Phase3 | Cancer-Associated Thrombosis (CAT) | Recruiting | 2026-03-09 | 2030-05-06 | ClinicalTrials.gov |
| NCT07187401 | A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA … | Phase1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Recruiting | 2026-02-11 | 2031-07-15 | ClinicalTrials.gov |
| NCT07220772 | A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mu… | Phase3 | Monogenic Obesity | Recruiting | 2026-02-09 | 2028-04-21 | ClinicalTrials.gov |
| NCT07234058 | Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus … | Phase2 | Pleural Mesotheliomas | Not_Yet_Recruiting | 2026-02-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT07230834 | Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants | Phase1 | Geographic Atrophy (GA) | Recruiting | 2026-01-19 | 2028-07-03 | ClinicalTrials.gov |
| NCT07223541 | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in … | Phase2 | Clear Cell Renal Cell Carcinoma | Recruiting | 2026-01-15 | 2031-08-01 | ClinicalTrials.gov |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplim… | Phase3 | Non-Small Cell Lung Cancer | Recruiting | 2026-01-12 | 2029-03-01 | ClinicalTrials.gov |
| NCT07309432 | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Ad… | Phase3 | Allergic Conjunctivitis | Recruiting | 2026-01-10 | 2027-06-15 | ClinicalTrials.gov |
| NCT07271186 | Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition… | Phase2 | Diabetic Kidney Disease (DKD) | Recruiting | 2026-01-09 | 2028-04-07 | ClinicalTrials.gov |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Co… | Phase3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Recruiting | 2026-01-02 | 2034-08-23 | ClinicalTrials.gov |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard… | Phase3 | Multiple Myeloma | Recruiting | 2025-12-23 | 2036-12-01 | ClinicalTrials.gov |
| NCT06975787 | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lup… | Phase1 | Lupus Nephritis (LN) | Recruiting | 2025-12-22 | 2029-09-09 | ClinicalTrials.gov |
| NCT07218770 | A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | Phase1 | Active Noninfectious Uveitis Affecting the Posterior Segment | Active_Not_Recruiting | 2025-12-17 | 2028-06-28 | ClinicalTrials.gov |
| NCT07216066 | First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's D… | Phase1 | Parkinsons Disease | Recruiting | 2025-12-05 | 2029-06-07 | ClinicalTrials.gov |
| NCT06910124 | Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of ND… | Phase2 | Multiple Myeloma | Recruiting | 2025-12-02 | 2032-12-02 | ClinicalTrials.gov |
| NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After … | Phase3 | Symptomatic Venous Thromboembolism (VTE) | Recruiting | 2025-11-24 | 2027-07-16 | ClinicalTrials.gov |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in … | — | Locally Advanced Melanoma | Recruiting | 2025-11-19 | 2031-11-01 | ClinicalTrials.gov |
| NCT07112378 | A Study of Dupilumab in Small Children With an Allergic Condition of the Esopha… | Phase3 | Eosinophilic Esophagitis (EoE) | Recruiting | 2025-11-10 | 2028-10-09 | ClinicalTrials.gov |
| NCT06798298 | A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated W… | — | Long Term Safety Following GM T Cell Therapy | Recruiting | 2025-11-10 | 2040-06-17 | ClinicalTrials.gov |
| NCT07251413 | Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneo… | Phase1 | Cutaneous Basal Cell Carcinoma | Recruiting | 2025-10-22 | 2028-12-01 | ClinicalTrials.gov |
| NCT07175428 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anti… | Phase2 | Atrial Fibrillation (AF) | Recruiting | 2025-10-20 | 2027-04-21 | ClinicalTrials.gov |
| NCT07128641 | Odronextamab in Low Tumor Volume Advanced FL | Phase2 | Follicular Lymphoma | Recruiting | 2025-09-08 | 2028-01-02 | ClinicalTrials.gov |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | Phase2 | Recurrent Diffuse Large B-Cell Lymphoma | Recruiting | 2025-09-04 | 2033-04-11 | ClinicalTrials.gov |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Mu… | Phase2 | Bladder Cancer | Recruiting | 2025-08-14 | 2028-12-01 | ClinicalTrials.gov |
| NCT06865339 | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non… | Phase2 | NSCLC | Recruiting | 2025-08-07 | 2027-08-01 | ClinicalTrials.gov |
| NCT06981325 | Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Adv… | Phase2 | Basal Cell Carcinoma (BCC) | Recruiting | 2025-08-07 | 2029-07-01 | ClinicalTrials.gov |
| NCT07064330 | Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxici… | — | Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | 2025-07-17 | 2027-06-01 | ClinicalTrials.gov |
| NCT07105228 | Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real… | — | Retinal Vasculitis | Completed | 2025-07-15 | 2025-09-15 | ClinicalTrials.gov |
| NCT06826768 | A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC | Phase1 | Prostate Cancer | Recruiting | 2025-07-09 | 2029-05-01 | ClinicalTrials.gov |
| NCT06662994 | High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitre… | Phase4 | Diabetic Macular Edema (DME) | Recruiting | 2025-07-07 | 2027-08-15 | ClinicalTrials.gov |
| NCT06651593 | Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumo… | Phase2 | Solid Tumors | Recruiting | 2025-07-02 | 2030-09-01 | ClinicalTrials.gov |
| NCT06769412 | A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among … | — | Retinal Vasculitis | Completed | 2025-07-01 | 2025-09-01 | ClinicalTrials.gov |
| NCT06019481 | A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF… | — | Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF) | Withdrawn | 2025-06-30 | 2030-06-30 | ClinicalTrials.gov |
| NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee… | Phase3 | Venous Thromboembolism (VTE) | Recruiting | 2025-06-25 | 2027-05-12 | ClinicalTrials.gov |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Phase1 | Anaplastic Thyroid Cancer | Recruiting | 2025-06-03 | 2028-08-31 | ClinicalTrials.gov |
| NCT06887088 | Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients Wi… | Phase2 | Melanoma BRAF V600E/K Mutated | Recruiting | 2025-05-29 | 2028-01-01 | ClinicalTrials.gov |
| NCT06970405 | Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopau… | Phase1 | Obesity | Withdrawn | 2025-05-29 | 2026-06-08 | ClinicalTrials.gov |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Plat… | Phase2 | Ovarian Cancer | Recruiting | 2025-05-28 | 2028-10-30 | ClinicalTrials.gov |
| NCT06616584 | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Adv… | Phase2 | Recurrent Lung Non-Small Cell Carcinoma | Recruiting | 2025-05-22 | 2028-12-31 | ClinicalTrials.gov |
| NCT06608901 | A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hyp… | Phase2 | Sepsis-Induced Hypotension | Completed | 2025-05-05 | 2026-04-28 | ClinicalTrials.gov |
| NCT06836609 | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-… | Phase1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Recruiting | 2025-04-28 | 2027-05-15 | ClinicalTrials.gov |
| NCT06833190 | REGN5381 in Adult Participants With Uncontrolled Hypertension | Phase2 | Uncontrolled Hypertension | Terminated | 2025-04-16 | 2025-10-15 | ClinicalTrials.gov |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previo… | Phase2 | Melanoma | Enrolling_By_Invitation | 2025-04-14 | 2029-10-10 | ClinicalTrials.gov |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | Phase2 | Non Small Cell Lung Cancer | Suspended | 2025-03-17 | 2029-10-30 | ClinicalTrials.gov |
| NCT06669234 | Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults | Phase1 | Healthy Volunteer | Active_Not_Recruiting | 2025-03-06 | 2026-07-30 | ClinicalTrials.gov |
| NCT06665828 | Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults | Phase1 | Healthy Volunteer | Completed | 2025-03-04 | 2026-01-29 | ClinicalTrials.gov |
| NCT06623656 | Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | Phase2 | Carcinoma, Non-Small-Cell Lung | Recruiting | 2025-02-21 | 2032-01-01 | ClinicalTrials.gov |
| NCT06784349 | ALN-APOC3 in Adult Participants With Dyslipidemia | Phase1 | Dyslipidemia | Completed | 2025-01-27 | 2026-02-25 | ClinicalTrials.gov |
| NCT06585410 | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous … | Phase3 | Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | 2025-01-02 | 2030-05-03 | ClinicalTrials.gov |
| NCT06548100 | A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switch… | Phase3 | Generalized Lipodystrophy | Active_Not_Recruiting | 2024-12-16 | 2026-11-03 | ClinicalTrials.gov |
| NCT06398080 | An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adul… | — | Neovascular Age-related Macular Degeneration (nAMD) | Withdrawn | 2024-12-12 | 2029-01-03 | ClinicalTrials.gov |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination… | Phase1 | Relapsed/Refractory Multiple Myeloma | Recruiting | 2024-12-11 | 2035-11-01 | ClinicalTrials.gov |
| NCT06672237 | A Phase 3 Study of NTLA-2001 in ATTRv-PN | Phase3 | Neuromuscular Disease | Recruiting | 2024-11-22 | 2028-08-01 | ClinicalTrials.gov |
| NCT06693531 | A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Pat… | — | Eosinophilic Esophagitis (EoE) | Recruiting | 2024-11-22 | 2030-05-22 | ClinicalTrials.gov |
| NCT06448026 | Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral … | Phase2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | Recruiting | 2024-11-21 | 2027-05-15 | ClinicalTrials.gov |
| NCT06226610 | Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic | Phase2 | Pruritis | Recruiting | 2024-11-21 | 2026-12-31 | ClinicalTrials.gov |
| NCT06602739 | A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy S… | Phase3 | Allergic Conjunctivitis | Completed | 2024-11-19 | 2025-08-02 | ClinicalTrials.gov |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plu… | Phase2 | Non-Small Cell Lung Cancer | Recruiting | 2024-11-18 | 2030-05-02 | ClinicalTrials.gov |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experim… | Phase2 | Cutaneous Squamous Cell Carcinoma | Withdrawn | 2024-11-14 | 2030-05-06 | ClinicalTrials.gov |
| NCT06593600 | Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients Wit… | Phase2 | Postural Orthostatic Tachycardia Syndrome (POTS) | Active_Not_Recruiting | 2024-11-13 | 2026-07-06 | ClinicalTrials.gov |
| NCT06665971 | Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Part… | Phase4 | Eosinophilic Esophagitis (EoE) | Recruiting | 2024-11-10 | 2026-11-14 | ClinicalTrials.gov |
| NCT06602726 | A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy … | Phase3 | Allergic Conjunctivitis | Completed | 2024-11-06 | 2025-08-02 | ClinicalTrials.gov |
| NCT06541704 | A Study Investigating Subcutaneously Administered Pozelimab in Combination With… | Phase3 | Age-related Macular Degeneration (AMD) | Recruiting | 2024-10-30 | 2032-05-21 | ClinicalTrials.gov |
| NCT06444880 | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-E… | Phase2 | SMARCB1-Deficient Malignancies | Recruiting | 2024-10-09 | 2028-07-31 | ClinicalTrials.gov |
| NCT06421636 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999… | Phase2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Active_Not_Recruiting | 2024-09-30 | 2026-12-03 | ClinicalTrials.gov |
| NCT06444178 | Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Pl… | Phase1 | Healthy Volunteers | Completed | 2024-09-30 | 2025-07-09 | ClinicalTrials.gov |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alon… | Phase1 | Melanoma | Recruiting | 2024-09-23 | 2030-02-03 | ClinicalTrials.gov |
| NCT06299111 | A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots… | Phase2 | Venous Thromboembolism | Completed | 2024-09-20 | 2026-03-27 | ClinicalTrials.gov |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti… | Phase2 | Melanoma | Active_Not_Recruiting | 2024-09-18 | 2030-12-09 | ClinicalTrials.gov |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal … | Phase2 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | Recruiting | 2024-09-16 | 2032-05-18 | ClinicalTrials.gov |
| NCT06379789 | A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX … | Phase1 | Hemophilia B | Recruiting | 2024-09-11 | 2047-08-14 | ClinicalTrials.gov |
| NCT06594991 | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | Phase2 | Advanced Melanoma | Recruiting | 2024-09-10 | 2027-09-01 | ClinicalTrials.gov |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Parti… | Phase3 | Melanoma | Recruiting | 2024-09-09 | 2033-07-10 | ClinicalTrials.gov |
| NCT06591598 | A Study to Learn About the Blood Levels of Aflibercept When High-dose Afliberce… | Phase4 | Diabetic Macular Edema | Completed | 2024-09-02 | 2025-10-14 | ClinicalTrials.gov |
| NCT06351592 | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic La… | Phase1 | Amyotrophic Lateral Sclerosis (ALS) | Recruiting | 2024-08-28 | 2032-03-21 | ClinicalTrials.gov |
| NCT06572228 | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting B… | Phase4 | Asthma | Active_Not_Recruiting | 2024-08-26 | 2027-04-24 | ClinicalTrials.gov |
| NCT06376526 | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma | Phase2 | Multiple Myeloma | Recruiting | 2024-08-21 | 2029-08-31 | ClinicalTrials.gov |
| NCT06479863 | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients… | Early_Phase1 | Sporadic Inclusion Body Myositis (sIBM) | Recruiting | 2024-08-08 | 2027-08-30 | ClinicalTrials.gov |
| NCT06292780 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or … | Phase1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | Recruiting | 2024-08-07 | 2035-02-20 | ClinicalTrials.gov |
| NCT06469281 | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell The… | Phase1 | Epithelial Ovarian Cancer | Recruiting | 2024-08-06 | 2030-05-27 | ClinicalTrials.gov |
| NCT06491914 | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult P… | Phase3 | Neovascular Age-Related Macular Degeneration | Active_Not_Recruiting | 2024-07-24 | 2027-01-07 | ClinicalTrials.gov |
| NCT06161441 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy … | Phase2 | Resectable Non-small Cell Lung Cancer | Active_Not_Recruiting | 2024-07-16 | 2029-11-04 | ClinicalTrials.gov |
| NCT06439654 | Atlantic Lipid Lowering Treatment Optimization Program | Na | Familial Hypercholesterolemia | Recruiting | 2024-07-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT06452771 | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe a… | Phase1 | Healthy Volunteers With Hyperlipidemia | Active_Not_Recruiting | 2024-06-27 | 2026-12-04 | ClinicalTrials.gov |
| NCT06454630 | A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Kne… | Phase2 | Venous Thromboembolism | Completed | 2024-06-27 | 2025-01-21 | ClinicalTrials.gov |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or … | Phase2 | Colorectal Cancer | Recruiting | 2024-06-13 | 2030-05-01 | ClinicalTrials.gov |
| NCT06422507 | A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe… | Phase3 | Diabetic Macular Edema | Completed | 2024-05-29 | 2026-03-25 | ClinicalTrials.gov |
| NCT06024408 | A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How… | Phase1 | Nonalcoholic Fatty Liver Disease (NAFLD) | Completed | 2024-05-21 | 2025-07-07 | ClinicalTrials.gov |
| NCT05961709 | The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Managemen… | Phase2 | Colon Cancer | Active_Not_Recruiting | 2024-05-20 | 2028-04-30 | ClinicalTrials.gov |
| NCT06369467 | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Ad… | Phase1 | Food Allergy | Active_Not_Recruiting | 2024-05-17 | 2027-08-31 | ClinicalTrials.gov |
| NCT05989126 | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | Phase3 | Diabetic Macular Edema (DME) | Completed | 2024-04-15 | 2024-05-31 | ClinicalTrials.gov |
| NCT06773897 | Rutgers University Study of the Genetics of Breast Cancer. | — | Breast Cancer Risk | Recruiting | 2024-04-15 | 2028-04-30 | ClinicalTrials.gov |
| NCT06237309 | REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction | Phase2 | Heart Failure | Terminated | 2024-04-11 | 2025-12-29 | ClinicalTrials.gov |
| NCT05031455 | Mechanisms of Dupilumab in AERD | Phase2 | Aspirin-exacerbated Respiratory Disease | Completed | 2024-03-25 | 2026-04-20 | ClinicalTrials.gov |
| NCT06122922 | Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) | Phase2 | Pulmonary Artery Hypertension | Withdrawn | 2024-03-15 | 2025-12-31 | ClinicalTrials.gov |
| NCT06299098 | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With S… | Phase2 | Obesity | Active_Not_Recruiting | 2024-03-13 | 2026-10-30 | ClinicalTrials.gov |
| NCT06269133 | Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in F… | — | Advanced Non-small Cell Lung Cancer | Active_Not_Recruiting | 2024-02-21 | 2027-06-23 | ClinicalTrials.gov |
| NCT06219629 | Parkinson's Disease Progression Study | — | Parkinson Disease | Active_Not_Recruiting | 2024-02-20 | 2026-02-01 | ClinicalTrials.gov |
| NCT06230224 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of… | Phase3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | Active_Not_Recruiting | 2024-02-15 | 2029-05-29 | ClinicalTrials.gov |
| NCT05955508 | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in A… | Phase2 | Smoldering Multiple Myeloma (SMM) | Active_Not_Recruiting | 2024-01-30 | 2033-01-25 | ClinicalTrials.gov |
| NCT05568459 | A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Parti… | — | Hemophilia B | Active_Not_Recruiting | 2024-01-17 | 2026-05-21 | ClinicalTrials.gov |
| NCT04046107 | Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on… | Phase1 | Hepatitis B Virus | Withdrawn | 2024-01-01 | 2027-09-30 | ClinicalTrials.gov |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Work… | Phase3 | Relapsed/Refractory Follicular Lymphoma | Recruiting | 2023-12-28 | 2029-01-23 | ClinicalTrials.gov |
| NCT06129552 | Basal Instincts: Towards Better Understanding of Basal Cell Function in Chronic… | — | Chronic Rhinosinusitis With Nasal Polyps | Recruiting | 2023-12-19 | 2027-12-01 | ClinicalTrials.gov |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolera… | Phase1 | Multiple Myeloma | Recruiting | 2023-12-19 | 2035-11-02 | ClinicalTrials.gov |
| NCT06128629 | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyl… | Phase3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Recruiting | 2023-12-13 | 2028-04-01 | ClinicalTrials.gov |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and H… | Phase3 | Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | 2023-12-13 | 2029-09-12 | ClinicalTrials.gov |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Wor… | Phase3 | Follicular Lymphoma (FL) | Recruiting | 2023-12-12 | 2029-11-03 | ClinicalTrials.gov |
| NCT06137482 | A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Adm… | Phase1 | Healthy Volunteers | Completed | 2023-12-06 | 2025-02-11 | ClinicalTrials.gov |
| NCT05923424 | A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2023-11-28 | 2025-03-04 | ClinicalTrials.gov |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-To… | Phase3 | Follicular Lymphoma (FL) | Active_Not_Recruiting | 2023-11-14 | 2029-07-29 | ClinicalTrials.gov |
| NCT05106387 | An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1… | — | Chronic Kidney Disease (CKD) | Recruiting | 2023-10-19 | 2028-02-23 | ClinicalTrials.gov |
| NCT06012448 | The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivit… | Phase4 | Dermal Hypersensitivity Reaction | Completed | 2023-10-02 | 2025-03-25 | ClinicalTrials.gov |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of El… | Phase3 | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting | 2023-09-18 | 2033-04-19 | ClinicalTrials.gov |
| NCT05704634 | A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-recepto… | Phase1 | Lung Cancer | Active_Not_Recruiting | 2023-08-18 | 2028-01-01 | ClinicalTrials.gov |
| NCT05800015 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemother… | Phase2 | Non-small Cell Lung Cancer | Active_Not_Recruiting | 2023-08-08 | 2031-12-23 | ClinicalTrials.gov |
| NCT05970718 | A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Parti… | Phase1 | Healthy Volunteers | Completed | 2023-08-07 | 2024-07-22 | ClinicalTrials.gov |
| NCT05929664 | Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck B… | Phase2 | Locally Advanced Basal Cell Carcinoma | Suspended | 2023-07-05 | 2031-07-05 | ClinicalTrials.gov |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | Phase1 | Cutaneous Squamous Cell Carcinoma | Withdrawn | 2023-07-01 | 2028-07-01 | ClinicalTrials.gov |
| NCT05785767 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab… | Phase2 | Advanced Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2023-06-30 | 2027-09-28 | ClinicalTrials.gov |
| NCT06064656 | A Non-Interventional Study of Clinical Characteristics and Mortality of US Pati… | — | Fibrodysplasia Ossificans Progressiva (FOP) | Completed | 2023-06-29 | 2023-09-29 | ClinicalTrials.gov |
| NCT05788536 | A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Child… | Phase1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Recruiting | 2023-06-27 | 2032-02-25 | ClinicalTrials.gov |
| NCT05618808 | A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee … | Phase2 | Venous Thromboembolism | Completed | 2023-05-24 | 2024-05-27 | ClinicalTrials.gov |
| NCT05553834 | PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To P… | Phase2 | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2023-05-16 | 2026-11-01 | ClinicalTrials.gov |
| NCT05831176 | A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants … | Phase2 | Eosinophilic Gastritis (EoG) | Active_Not_Recruiting | 2023-05-03 | 2026-11-25 | ClinicalTrials.gov |
| NCT05685173 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult… | Phase1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | Recruiting | 2023-04-20 | 2030-01-13 | ClinicalTrials.gov |
| NCT05551793 | Regeneron AA Multicenter (Dupilumab) | Phase2 | Alopecia Areata | Recruiting | 2023-04-10 | 2028-10-31 | ClinicalTrials.gov |
| NCT05720325 | Dupilumab Effects Against Aeroallergen Challenge | Phase2 | Asthma, Allergic | Active_Not_Recruiting | 2023-03-29 | 2027-11-01 | ClinicalTrials.gov |
| NCT05744921 | A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Eva… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 2023-03-07 | 2029-02-26 | ClinicalTrials.gov |
| NCT05478824 | IL13 Signaling in Allergic Asthma | — | Asthma, Allergic | Completed | 2023-02-21 | 2025-11-11 | ClinicalTrials.gov |
| NCT05519475 | A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Dis… | Phase2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | Recruiting | 2023-02-09 | 2028-12-07 | ClinicalTrials.gov |
| NCT05259709 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With… | Phase1 | Advanced Solid Tumor | Recruiting | 2023-02-07 | 2027-01-06 | ClinicalTrials.gov |
| NCT05268107 | Ethnic Differences in Mechanisms of Action of Dupilumab | Phase4 | Atopic Dermatitis | Recruiting | 2023-01-25 | 2027-06-01 | ClinicalTrials.gov |
| NCT05608291 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Tha… | Phase3 | Melanoma | Active_Not_Recruiting | 2023-01-16 | 2030-04-03 | ClinicalTrials.gov |
| NCT05128383 | Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids | Phase2 | Keloid | Completed | 2023-01-13 | 2025-06-10 | ClinicalTrials.gov |
| NCT05603195 | A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Saf… | Phase1 | Healthy Volunteer | Completed | 2023-01-12 | 2024-09-17 | ClinicalTrials.gov |
| NCT05590585 | Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Modera… | Phase4 | Moderate-to-Severe Atopic Dermatitis | Completed | 2023-01-11 | 2024-11-14 | ClinicalTrials.gov |
| NCT05673967 | Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myel… | — | Relapsed and Refractory Multiple Myeloma (RRMM) | Completed | 2023-01-09 | 2025-03-28 | ClinicalTrials.gov |
| NCT05546957 | Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Riva… | Na | Healthy Volunteer | Completed | 2023-01-05 | 2023-04-06 | ClinicalTrials.gov |
| NCT05469347 | Alirocumab in Patients with Sepsis | Phase1 | Sepsis | Completed | 2023-01-04 | 2025-02-23 | ClinicalTrials.gov |
| NCT05648214 | A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Ad… | Phase1 | Healthy Volunteers | Recruiting | 2022-12-27 | 2027-08-10 | ClinicalTrials.gov |
| NCT05394116 | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placeb… | Phase3 | Fibrodysplasia Ossificans Progressiva | Active_Not_Recruiting | 2022-11-21 | 2029-02-27 | ClinicalTrials.gov |
| NCT05363319 | An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab i… | — | Non-small Cell Lung Cancer | Recruiting | 2022-10-26 | 2028-10-30 | ClinicalTrials.gov |
| NCT05481333 | A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in th… | Phase1 | Healthy | Completed | 2022-10-24 | 2023-08-29 | ClinicalTrials.gov |
| NCT05131204 | Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Conti… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2022-10-06 | 2023-07-12 | ClinicalTrials.gov |
| NCT05791695 | A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmi… | — | Intraocular Inflammation | Completed | 2022-09-16 | 2023-09-15 | ClinicalTrials.gov |
| NCT05505448 | A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How … | Phase1 | Healthy | Completed | 2022-09-15 | 2023-05-30 | ClinicalTrials.gov |
| NCT05094570 | Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and… | Phase4 | Nasal Polyps | Recruiting | 2022-09-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination Wi… | Phase1 | Multiple Myeloma | Recruiting | 2022-08-17 | 2032-03-24 | ClinicalTrials.gov |
| NCT05430919 | Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Re… | Phase2 | Allergic Rhinitis | Completed | 2022-08-15 | 2023-07-31 | ClinicalTrials.gov |
| NCT05092347 | A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Ch… | Phase1 | Chronic Kidney Disease (CKD) | Active_Not_Recruiting | 2022-08-02 | 2027-11-22 | ClinicalTrials.gov |
| NCT05133531 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and … | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2022-08-01 | 2026-10-26 | ClinicalTrials.gov |
| NCT05376553 | Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanc… | Phase1 | Locally Advanced Head and Neck Squamous Cell Carcinoma | Enrolling_By_Invitation | 2022-07-20 | 2025-10-01 | ClinicalTrials.gov |
| NCT05352672 | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab… | Phase3 | Melanoma | Active_Not_Recruiting | 2022-07-14 | 2031-09-16 | ClinicalTrials.gov |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcino… | Phase2 | Head and Neck Squamous Cell Carcinoma | Withdrawn | 2022-07-01 | 2022-07-15 | ClinicalTrials.gov |
| NCT05353166 | REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary … | Phase2 | Heart Failure | Completed | 2022-06-30 | 2025-06-02 | ClinicalTrials.gov |
| NCT05338879 | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment … | — | Relapsed/Refractory Follicular Lymphoma | Completed | 2022-06-22 | 2023-10-05 | ClinicalTrials.gov |
| NCT05338892 | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment … | — | Diffuse Large B-Cell Lymphoma | Completed | 2022-06-22 | 2023-10-05 | ClinicalTrials.gov |
| NCT05347771 | Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adoles… | Phase2 | Asthma | Active_Not_Recruiting | 2022-05-04 | 2027-03-15 | ClinicalTrials.gov |
| NCT04380038 | Viral Infection in Asthma (VIA) Study | Phase4 | Asthma | Recruiting | 2022-05-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05285839 | Dupixent and Narrowband UVB for Atopic Dermatitis | Phase4 | Atopic Dermatitis | Recruiting | 2022-04-19 | 2024-12-15 | ClinicalTrials.gov |
| NCT05291546 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Volunteers | Completed | 2022-04-13 | 2024-04-02 | ClinicalTrials.gov |
| NCT05293678 | Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in… | Phase1 | Healthy | Completed | 2022-04-12 | 2023-01-26 | ClinicalTrials.gov |
| NCT05265234 | Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging. | Phase4 | Eczema | Unknown | 2022-03-01 | 2024-03-01 | ClinicalTrials.gov |
| NCT05088460 | A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody R… | Phase2 | Familial Partial Lipodystrophy | Terminated | 2022-02-28 | 2024-04-18 | ClinicalTrials.gov |
| NCT05036733 | Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and … | Phase4 | Asthma | Completed | 2022-02-22 | 2023-06-29 | ClinicalTrials.gov |
| NCT05246267 | Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rh… | — | Chronic Rhinosinusitis With Nasal Polyps | Recruiting | 2022-02-15 | 2026-06-01 | ClinicalTrials.gov |
| NCT05169489 | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (… | Phase1 | Diffuse Large B Cell Lymphoma (DLBCL) | Terminated | 2022-01-24 | 2025-09-19 | ClinicalTrials.gov |
| NCT04706715 | LAG3 PET Imaging in Advanced Solid Tumors | Phase1 | Metastatic Solid Tumor | Active_Not_Recruiting | 2022-01-18 | 2025-11-01 | ClinicalTrials.gov |
| NCT05181683 | COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spik… | Phase1 | Healthy | Completed | 2022-01-07 | 2022-06-03 | ClinicalTrials.gov |
| NCT05157997 | Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipie… | Phase1 | COVID-19 | Withdrawn | 2022-01-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT05092581 | COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intra… | Phase1 | COVID-19 | Terminated | 2021-12-16 | 2022-06-09 | ClinicalTrials.gov |
| NCT05070858 | A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdi… | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2021-12-14 | 2028-11-11 | ClinicalTrials.gov |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for … | Phase2 | HPV-Related Squamous Cell Carcinoma | Recruiting | 2021-12-13 | 2027-12-01 | ClinicalTrials.gov |
| NCT05423327 | Genetic Data Collection in Adult Participants to Identify Genetic Variants of K… | Na | Non-alcoholic Steatohepatitis (NASH) | Terminated | 2021-12-09 | 2022-10-27 | ClinicalTrials.gov |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It W… | Phase2 | Merkel Cell Carcinoma | Terminated | 2021-11-30 | 2024-10-31 | ClinicalTrials.gov |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Comb… | Phase1 | Metastatic Castration-resistant Prostate Cancer | Recruiting | 2021-11-30 | 2030-03-28 | ClinicalTrials.gov |
| NCT05105152 | PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With R… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2021-11-29 | 2041-01-31 | ClinicalTrials.gov |
| NCT04982224 | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With… | Phase1 | Advanced NSCLC | Terminated | 2021-11-09 | 2025-10-15 | ClinicalTrials.gov |
| NCT05081388 | COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imde… | Phase1 | SARS-CoV-2 | Terminated | 2021-11-08 | 2022-06-30 | ClinicalTrials.gov |
| NCT05102136 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Volunteers | Completed | 2021-10-27 | 2023-04-04 | ClinicalTrials.gov |
| NCT05074433 | A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal An… | Phase3 | Immunocompromised | Terminated | 2021-10-25 | 2022-05-18 | ClinicalTrials.gov |
| NCT04975152 | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell C… | Phase1 | Merkel Cell Carcinoma | Recruiting | 2021-10-22 | 2028-03-01 | ClinicalTrials.gov |
| NCT04148352 | Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy | Phase2 | Allergies Food Milk | Terminated | 2021-10-18 | 2025-02-25 | ClinicalTrials.gov |
| NCT04577820 | Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patient… | Phase3 | Fibrodyplasia Ossificans Progressiva (FOP) | Withdrawn | 2021-10-13 | 2022-10-08 | ClinicalTrials.gov |
| NCT05064085 | Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast C… | Phase1 | Hormone Receptor-positive Breast Cancer | Completed | 2021-10-12 | 2025-03-13 | ClinicalTrials.gov |
| NCT04992273 | COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 M… | Phase2 | COVID-19 | Terminated | 2021-09-13 | 2022-06-01 | ClinicalTrials.gov |
| NCT05013723 | Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome | — | Post-acute COVID-19 (PACS), or "long COVID" Syndrome | Completed | 2021-08-30 | 2022-12-16 | ClinicalTrials.gov |
| NCT04940364 | A Study to Examine the Safety, Tolerability and Biological Effects of Single Do… | Phase1 | Healthy | Completed | 2021-08-04 | 2022-06-22 | ClinicalTrials.gov |
| NCT04981717 | A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injection… | Phase3 | Allergic Rhinitis Due to Cat Allergy | Terminated | 2021-07-30 | 2023-04-24 | ClinicalTrials.gov |
| NCT04811716 | Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Parox… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2021-07-29 | 2023-10-18 | ClinicalTrials.gov |
| NCT04863014 | Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceri… | Phase2 | Hypertriglyceridemia | Terminated | 2021-07-12 | 2023-02-15 | ClinicalTrials.gov |
| NCT04888507 | Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxys… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2021-07-08 | 2023-05-04 | ClinicalTrials.gov |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastati… | Phase2 | Squamous Cell Carcinoma of the Oropharynx | Unknown | 2021-07-01 | 2024-12-30 | ClinicalTrials.gov |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic … | Phase2 | Cervical Cancer | Completed | 2021-06-28 | 2024-05-29 | ClinicalTrials.gov |
| NCT04708145 | Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Tr… | Phase4 | Diabetic Retinopathy | Completed | 2021-06-01 | 2024-07-31 | ClinicalTrials.gov |
| NCT03678545 | Dupilumab in Eosinophilic Gastritis | Phase2 | Eosinophilic Gastritis | Completed | 2021-05-15 | 2024-11-13 | ClinicalTrials.gov |
| NCT04852978 | COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mR… | Phase2 | Healthy | Completed | 2021-04-29 | 2022-11-21 | ClinicalTrials.gov |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subj… | Phase2 | Melanoma | Terminated | 2021-02-24 | 2024-07-22 | ClinicalTrials.gov |
| NCT04515524 | Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Re… | — | Retinopathy of Prematurity | Active_Not_Recruiting | 2021-02-05 | 2026-11-05 | ClinicalTrials.gov |
| NCT04633278 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metasta… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Terminated | 2021-01-21 | 2024-01-19 | ClinicalTrials.gov |
| NCT04722523 | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head a… | Phase1 | Head and Neck Cancer | Recruiting | 2021-01-20 | 2026-06-20 | ClinicalTrials.gov |
| NCT04709575 | Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to… | Phase3 | Allergic Rhinitis | Completed | 2021-01-14 | 2021-08-24 | ClinicalTrials.gov |
| NCT04409080 | REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or… | Phase1 | Severe Aplastic Anemia (SAA) | Terminated | 2021-01-13 | 2024-10-17 | ClinicalTrials.gov |
| NCT04626635 | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination W… | Phase1 | Advanced Solid Tumors | Active_Not_Recruiting | 2020-12-21 | 2027-03-05 | ClinicalTrials.gov |
| NCT04666441 | COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across D… | Phase2 | COVID-19 | Completed | 2020-12-15 | 2021-09-21 | ClinicalTrials.gov |
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women W… | Phase1 | Ovarian Cancer | Recruiting | 2020-12-08 | 2027-11-30 | ClinicalTrials.gov |
| NCT04588948 | A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized … | Phase2 | Diabetic Macular Edema | Withdrawn | 2020-12-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT04616079 | Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volu… | Phase1 | Healthy Volunteer | Terminated | 2020-11-19 | 2021-06-01 | ClinicalTrials.gov |
| NCT04616105 | Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy … | Phase1 | Healthy Volunteer | Terminated | 2020-11-18 | 2021-05-28 | ClinicalTrials.gov |
| NCT04601844 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Co… | Phase1 | Healthy | Completed | 2020-11-16 | 2021-07-23 | ClinicalTrials.gov |
| NCT04543071 | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy … | Phase2 | Pancreatic Cancer | Recruiting | 2020-11-09 | 2028-08-01 | ClinicalTrials.gov |
| NCT04502966 | Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction | Phase2 | Allergic Rhinoconjunctivitis | Completed | 2020-11-05 | 2025-02-20 | ClinicalTrials.gov |
| NCT04339062 | Cemiplimab in AlloSCT/SOT Recipients With CSCC | Phase1 | Cutaneous Squamous Cell Carcinoma | Completed | 2020-11-03 | 2025-03-01 | ClinicalTrials.gov |
| NCT04614571 | T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac … | Na | Celiac Disease | Completed | 2020-11-02 | 2024-05-30 | ClinicalTrials.gov |
| NCT04311606 | Anti-VEGF Therapy for Acute Thyroid Eye Disease | Phase2 | Thyroid Eye Disease | Completed | 2020-11-02 | 2024-12-17 | ClinicalTrials.gov |
| NCT04206553 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With… | Phase2 | Bullous Pemphigoid | Completed | 2020-10-28 | 2025-01-05 | ClinicalTrials.gov |
| NCT04362501 | Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Po… | Phase2 | Chronic Sinusitis | Completed | 2020-10-15 | 2025-09-30 | ClinicalTrials.gov |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Ma… | Phase1 | Squamous Cell Carcinoma of Head and Neck | Terminated | 2020-10-05 | 2025-02-07 | ClinicalTrials.gov |
| NCT04256759 | Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus | Phase2 | Pruritus | Completed | 2020-09-01 | 2024-09-06 | ClinicalTrials.gov |
| NCT04520308 | An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With A… | Phase4 | Atopic Dermatitis | Unknown | 2020-09-01 | 2021-03-31 | ClinicalTrials.gov |
| NCT04506645 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an … | Phase1 | Healthy | Completed | 2020-09-01 | 2022-12-14 | ClinicalTrials.gov |
| NCT04423718 | Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients… | Phase3 | Neovascular Age-Related Macular Degeneration | Completed | 2020-08-11 | 2024-08-07 | ClinicalTrials.gov |
| NCT04491838 | Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Ma… | Phase1 | Healthy Volunteer | Completed | 2020-08-03 | 2021-03-05 | ClinicalTrials.gov |
| NCT04519437 | Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity … | Phase1 | Healthy | Completed | 2020-07-26 | 2021-11-22 | ClinicalTrials.gov |
| NCT04203797 | A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patie… | Phase4 | Asthma | Completed | 2020-07-16 | 2023-07-15 | ClinicalTrials.gov |
| NCT04452318 | COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoc… | Phase3 | Healthy Participants | Completed | 2020-07-13 | 2021-10-04 | ClinicalTrials.gov |
| NCT04429503 | Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease | Phase2 | Diabetic Macular Edema | Completed | 2020-06-29 | 2024-06-18 | ClinicalTrials.gov |
| NCT04233918 | Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homoz… | Phase3 | Homozygous Familial Hypercholesterolemia | Completed | 2020-06-29 | 2023-05-30 | ClinicalTrials.gov |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase2 | Cutaneous Squamous Cell Carcinoma | Terminated | 2020-06-25 | 2022-05-26 | ClinicalTrials.gov |
| NCT04425629 | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Anti… | Phase3 | COVID-19 | Terminated | 2020-06-16 | 2022-06-09 | ClinicalTrials.gov |
| NCT04426695 | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Anti… | Phase1 | COVID-19 | Completed | 2020-06-10 | 2021-10-22 | ClinicalTrials.gov |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Phase2 | Melanoma | Active_Not_Recruiting | 2020-04-24 | 2026-12-01 | ClinicalTrials.gov |
| NCT04015180 | Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 | Phase3 | Retinopathy of Prematurity (ROP) | Completed | 2020-03-18 | 2025-09-19 | ClinicalTrials.gov |
| NCT04287621 | Registry of Asthma Patients Initiating DUPIXENT® | — | Asthma | Completed | 2020-03-02 | 2026-04-27 | ClinicalTrials.gov |
| NCT04296864 | Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC) | Phase2 | Atopic Keratoconjunctivitis | Unknown | 2020-02-10 | 2025-01-01 | ClinicalTrials.gov |
| NCT04209634 | Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficie… | Phase2 | CD55-deficient Protein-losing Enteropathy | Completed | 2020-01-27 | 2024-05-02 | ClinicalTrials.gov |
| NCT04077099 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Fa… | Phase1 | NSCLC | Recruiting | 2020-01-07 | 2032-04-22 | ClinicalTrials.gov |
| NCT04159415 | Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With General… | Phase2 | Generalized Lipodystrophy | Completed | 2020-01-07 | 2024-09-24 | ClinicalTrials.gov |
| NCT03750760 | Early Alirocumab to Reduce LDL-C in Myocardial Infarction | Phase4 | Myocardial Infarction | Withdrawn | 2020-01-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT03935971 | The Effects of Dupilumab on Allergic Contact Dermatitis | Phase4 | Allergic Contact Dermatitis | Active_Not_Recruiting | 2019-12-18 | 2026-07-31 | ClinicalTrials.gov |
| NCT04162470 | REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2019-12-03 | 2022-04-07 | ClinicalTrials.gov |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult P… | Phase2 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Active_Not_Recruiting | 2019-11-13 | 2028-12-15 | ClinicalTrials.gov |
| NCT04126317 | Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular … | Phase2 | Neovascular (Wet) Age-Related Macular Degeneration | Completed | 2019-11-04 | 2021-11-30 | ClinicalTrials.gov |
| NCT04101721 | Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Afliberc… | Phase3 | Retinopathy of Prematurity | Completed | 2019-10-30 | 2022-08-18 | ClinicalTrials.gov |
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Sq… | Phase2 | Cutaneous Squamous Cell Carcinoma | Active_Not_Recruiting | 2019-10-08 | 2025-09-01 | ClinicalTrials.gov |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refra… | Phase1 | Relapsed Multiple Myeloma | Completed | 2019-09-26 | 2025-05-01 | ClinicalTrials.gov |
| NCT04004208 | Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Lase… | Phase3 | Retinopathy of Prematurity (ROP) | Completed | 2019-09-25 | 2021-02-12 | ClinicalTrials.gov |
| NCT03746704 | Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult … | Phase1 | Advanced PD-L1 Positive Malignancies | Terminated | 2019-09-04 | 2021-07-08 | ClinicalTrials.gov |
| NCT03679845 | Study to Assess Sarilumab in Halting Progression of Morphea | Phase1 | Morphea, Plaque Form | Withdrawn | 2019-09-01 | 2021-06-30 | ClinicalTrials.gov |
| NCT03886493 | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | Phase2 | Prostate Cancer | Terminated | 2019-08-28 | 2020-10-06 | ClinicalTrials.gov |
| NCT03787095 | Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in … | Phase1 | HIV Infections | Terminated | 2019-08-13 | 2020-08-18 | ClinicalTrials.gov |
| NCT03972657 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alon… | Phase1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Recruiting | 2019-08-12 | 2027-11-15 | ClinicalTrials.gov |
| NCT03712904 | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With U… | Phase2 | Uveal Melanoma | Terminated | 2019-08-09 | 2022-12-23 | ClinicalTrials.gov |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in… | Phase2 | Non-small Cell Lung Cancer | Active_Not_Recruiting | 2019-07-23 | 2030-05-14 | ClinicalTrials.gov |
| NCT03836105 | CemiplimAb Survivorship Epidemiology | — | Cutaneous Squamous Cell Carcinoma | Completed | 2019-06-27 | 2025-09-29 | ClinicalTrials.gov |
| NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy… | Phase3 | Cutaneous Squamous Cell Carcinoma | Active_Not_Recruiting | 2019-06-04 | 2028-01-07 | ClinicalTrials.gov |
| NCT03969849 | Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic … | Phase1 | Healthy Volunteers | Completed | 2019-06-03 | 2020-03-27 | ClinicalTrials.gov |
| NCT03956550 | A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Du… | Phase2 | Osteoarthritis of the Knee | Terminated | 2019-05-21 | 2020-10-29 | ClinicalTrials.gov |
| NCT03951831 | REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive … | Phase2 | Prostate Cancer Metastatic | Active_Not_Recruiting | 2019-05-16 | 2028-04-01 | ClinicalTrials.gov |
| NCT03946748 | Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysm… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2019-05-16 | 2021-06-10 | ClinicalTrials.gov |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcin… | Phase1 | Cutaneous Squamous Cell Carcinoma | Completed | 2019-04-11 | 2025-12-10 | ClinicalTrials.gov |
| NCT03396861 | Treatment of Macular Edema After Cataract Surgery with Subconjunctival Afliberc… | Phase1 | Irvine-Gass Syndrome | Terminated | 2019-02-22 | 2020-01-02 | ClinicalTrials.gov |
| NCT03710941 | Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Bo… | Phase2 | Sporadic Inclusion Body Myositis | Withdrawn | 2019-02-19 | 2020-11-05 | ClinicalTrials.gov |
| NCT03838731 | Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single… | Phase2 | Cat Allergy | Completed | 2019-02-12 | 2020-04-06 | ClinicalTrials.gov |
| NCT03344692 | Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabe… | Phase3 | Type2 Diabetes | Completed | 2019-02-12 | 2022-04-28 | ClinicalTrials.gov |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory … | Phase1 | Multiple Myeloma | Recruiting | 2019-01-23 | 2033-06-16 | ClinicalTrials.gov |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surg… | Phase1 | Stage III Prostate Cancer | Withdrawn | 2018-12-24 | 2019-11-04 | ClinicalTrials.gov |
| NCT03767738 | Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe | Phase4 | Chorioretinal Vascular Disease | Completed | 2018-12-19 | 2020-08-19 | ClinicalTrials.gov |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | Phase2 | Squamous Cell Carcinoma of the Oropharynx | Unknown | 2018-11-30 | 2025-06-01 | ClinicalTrials.gov |
| NCT03667014 | The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermati… | Phase4 | Atopic Dermatitis | Completed | 2018-11-01 | 2022-12-15 | ClinicalTrials.gov |
| NCT03507374 | PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis | Early_Phase1 | Stroke | Terminated | 2018-10-30 | 2020-04-17 | ClinicalTrials.gov |
| NCT03639675 | Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Incr… | Phase3 | Glaucoma, Neovascular | Completed | 2018-10-03 | 2019-03-14 | ClinicalTrials.gov |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nerv… | Phase1 | Relapsed Solid Tumor | Terminated | 2018-09-24 | 2023-05-10 | ClinicalTrials.gov |
| NCT03645746 | Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2018-08-23 | 2019-09-30 | ClinicalTrials.gov |
| NCT03542110 | The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Graft… | Phase4 | Saphenous Vein Graft Atherosclerosis | Terminated | 2018-08-04 | 2020-07-31 | ClinicalTrials.gov |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or M… | Phase1 | Carcinoma, Non-Small-Cell Lung | Terminated | 2018-06-27 | 2019-12-04 | ClinicalTrials.gov |
| NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal … | Phase1 | Renal Cell Carcinoma | Completed | 2018-06-19 | 2023-02-16 | ClinicalTrials.gov |
| NCT03452228 | Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patie… | Phase2 | Severe Hypertriglyceridemia (sHTG) | Completed | 2018-06-07 | 2020-07-23 | ClinicalTrials.gov |
| NCT03059277 | Intravitreal Alfibercept for Center Involved DME Previously Managed With Intrav… | Phase4 | Diabetic Macular Edema | Withdrawn | 2018-06-01 | 2020-09-30 | ClinicalTrials.gov |
| NCT03531294 | Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve… | Phase2 | Diabetic Retinopathy | Completed | 2018-05-23 | 2021-04-09 | ClinicalTrials.gov |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemipl… | Phase1 | Recurrent Ovarian Cancer | Recruiting | 2018-05-21 | 2027-05-10 | ClinicalTrials.gov |
| NCT03480568 | Alirocumab in Patients on a Stable Dialysis Regimen | Phase3 | Hemodialysis | Unknown | 2018-05-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT03530514 | A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 … | Phase1 | Healthy Volunteers | Completed | 2018-04-24 | 2020-01-27 | ClinicalTrials.gov |
| NCT03468296 | Two-week Retreatment Interval Study for Treated Age-related Macular Degeneratio… | Phase4 | Neovascular Age-related Macular Degeneration | Unknown | 2018-04-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT03438318 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With … | Phase1 | Non Small Cell Lung Cancer | Completed | 2018-03-15 | 2019-12-11 | ClinicalTrials.gov |
| NCT03409744 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homoz… | Phase3 | Homozygous Familial Hypercholesterolemia | Completed | 2018-03-13 | 2023-04-13 | ClinicalTrials.gov |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chem… | Phase3 | Non-small Cell Lung Cancer | Completed | 2018-03-06 | 2025-02-27 | ClinicalTrials.gov |
| NCT03411941 | Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clini… | — | Macular Degeneration | Completed | 2018-02-28 | 2019-03-01 | ClinicalTrials.gov |
| NCT03188666 | A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Format… | Phase2 | Fibrodysplasia Ossificans Progressiva | Completed | 2018-02-26 | 2021-09-16 | ClinicalTrials.gov |
| NCT03399786 | Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercho… | Phase3 | Homozygous Familial Hypercholesterolemia | Completed | 2018-01-18 | 2020-03-17 | ClinicalTrials.gov |
| NCT03382587 | Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Tr… | — | Wet Age-related Macular Degeneration | Completed | 2017-12-05 | 2018-11-27 | ClinicalTrials.gov |
| NCT03161912 | A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients W… | — | Macular Edema | Completed | 2017-11-24 | 2021-12-17 | ClinicalTrials.gov |
| NCT03175367 | Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterol… | Phase2 | Hypercholesterolemia | Completed | 2017-11-10 | 2020-12-14 | ClinicalTrials.gov |
| NCT03278262 | The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Trea… | — | Wet Macular Degeneration | Completed | 2017-09-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT03085784 | Intravitreal Aflibercept Injection for Radiation Retinopathy Trial | Phase2 | Radiation Retinopathy | Unknown | 2017-07-05 | 2021-10-01 | ClinicalTrials.gov |
| NCT03233139 | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-… | Phase1 | Advanced Malignancies | Active_Not_Recruiting | 2017-06-21 | 2027-09-30 | ClinicalTrials.gov |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants Wi… | Phase3 | Carcinoma，Non-Small-Cell Lung | Completed | 2017-05-29 | 2025-04-18 | ClinicalTrials.gov |
| NCT03146416 | Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2017-05-16 | 2018-06-14 | ClinicalTrials.gov |
| NCT03115996 | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RE… | Phase1 | Healthy Volunteers | Completed | 2017-05-10 | 2018-08-31 | ClinicalTrials.gov |
| NCT03084640 | Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Co… | Phase1 | Malignant Melanoma | Completed | 2017-05-04 | 2021-09-30 | ClinicalTrials.gov |
| NCT03067844 | Vascular Effects of Alirocumab in Acute MI-Patients | Phase3 | Coronary Vessel | Completed | 2017-04-25 | 2021-10-13 | ClinicalTrials.gov |
| NCT03022292 | The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy | Phase4 | Wet Macular Degeneration | Completed | 2017-03-30 | 2020-08-31 | ClinicalTrials.gov |
| NCT02828033 | Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss | Early_Phase1 | Autoimmune Neurosensory Hearing Loss (ANSHL) | Unknown | 2017-02-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT03004001 | Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Sy… | Phase2 | Nephrotic Syndrome | Terminated | 2017-01-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02943239 | Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Co… | Phase1 | Healthy Volunteers | Completed | 2016-12-08 | 2019-04-30 | ClinicalTrials.gov |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects Wi… | Phase1 | Metastatic Castration-resistant Prostate Cancer | Terminated | 2016-11-30 | 2023-03-14 | ClinicalTrials.gov |
| NCT03005782 | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced … | Phase1 | Malignancies | Completed | 2016-11-07 | 2024-04-02 | ClinicalTrials.gov |
| NCT02858076 | Anti-VEGF vs. Prompt Vitrectomy for VH From PDR | Phase2 | Proliferative Diabetic Retinopathy | Completed | 2016-11-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT02992301 | Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Ali… | Phase4 | Atherosclerosis | Unknown | 2016-11-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT04722068 | Regeneron 1331 Kinetics Sub-Study HoFH | Na | Hypercholesterolemia, Familial | Completed | 2016-10-07 | 2021-01-01 | ClinicalTrials.gov |
| NCT02811692 | Study for Collection of Aflibercept Data in Routine Practice | — | Eye Diseases | Completed | 2016-09-30 | 2017-11-27 | ClinicalTrials.gov |
| NCT02924311 | Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Pati… | — | Diabetic Retinopathy | Completed | 2016-09-21 | 2019-12-06 | ClinicalTrials.gov |
| NCT02863354 | Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Re… | Phase2 | Proliferative Diabetic Retinopathy | Completed | 2016-08-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT02870400 | A Study to Examine the Safety and Tolerability of Single Ascending Doses of REG… | Phase1 | Healthy Volunteers | Completed | 2016-07-01 | 2017-01-12 | ClinicalTrials.gov |
| NCT02777151 | Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in He… | Phase1 | Healthy Volunteers | Completed | 2016-05-27 | 2017-04-26 | ClinicalTrials.gov |
| NCT02680184 | Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy | Phase1 | Melanoma | Completed | 2016-04-12 | 2022-12-06 | ClinicalTrials.gov |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Phase2 | Advanced Cutaneous Squamous Cell Carcinoma | Completed | 2016-04-07 | 2023-10-18 | ClinicalTrials.gov |
| NCT02828397 | Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Su… | Phase1 | Healthy Volunteers | Completed | 2016-04-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02713204 | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY f… | Phase2 | Neovascular Age-Related Macular Degeneration | Completed | 2016-03-31 | 2017-10-03 | ClinicalTrials.gov |
| NCT02718326 | Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Impr… | Phase3 | Nonproliferative Diabetic Retinopathy | Completed | 2016-03-29 | 2019-07-16 | ClinicalTrials.gov |
| NCT02712008 | Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBi… | Phase2 | Diabetic Macular Edema | Completed | 2016-03-02 | 2017-07-10 | ClinicalTrials.gov |
| NCT02741739 | Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Su… | Phase1 | Healthy | Completed | 2016-03-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02585401 | Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibe… | — | Age-related Macular Degeneration (AMD) | Completed | 2016-02-18 | 2016-05-19 | ClinicalTrials.gov |
| NCT02321241 | Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Obser… | — | Wet Macular Degeneration | Completed | 2016-02-01 | 2017-08-18 | ClinicalTrials.gov |
| NCT02620020 | A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of … | Phase2 | Low Back Pain | Completed | 2016-01-26 | 2017-09-13 | ClinicalTrials.gov |
| NCT02645747 | Retrospective Data Analysis of Patients Treated for Macular Edema Due to Centra… | — | Retinal Vein Occlusion | Completed | 2016-01-21 | 2017-12-23 | ClinicalTrials.gov |
| NCT02651662 | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adul… | Phase1 | Relapsed/Refractory Aggressive B-Cell Lymphoma | Completed | 2016-01-11 | 2026-04-29 | ClinicalTrials.gov |
| NCT02634333 | Anti-VEGF Treatment for Prevention of PDR/DME | Phase3 | Diabetic Retinopathy | Completed | 2016-01-01 | 2022-05-11 | ClinicalTrials.gov |
| NCT02540369 | To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as We… | — | Wet Macular Degeneration | Completed | 2015-12-14 | 2018-01-26 | ClinicalTrials.gov |
| NCT02581891 | Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Y… | Phase4 | Macular Degeneration | Completed | 2015-11-19 | 2019-04-26 | ClinicalTrials.gov |
| NCT02612454 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants … | Phase3 | Atopic Dermatitis | Active_Not_Recruiting | 2015-10-15 | 2026-10-07 | ClinicalTrials.gov |
| NCT02559180 | Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Tre… | Phase4 | Diabetic Retinopathy | Completed | 2015-10-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02541084 | Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan | — | Wet Macular Degeneration | Completed | 2015-08-18 | 2016-07-30 | ClinicalTrials.gov |
| NCT02503540 | Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO | Phase4 | Retinal Vein Occlusion | Completed | 2015-08-18 | 2018-02-06 | ClinicalTrials.gov |
| NCT02520245 | Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD… | Phase1 | Advanced Malignancies | Withdrawn | 2015-08-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT02325791 | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prev… | Phase3 | Respiratory Syncytial Virus Infections | Completed | 2015-07-21 | 2017-09-26 | ClinicalTrials.gov |
| NCT02516618 | Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects | Phase1 | Healthy Volunteers | Completed | 2015-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02462889 | IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD | Phase2 | Age-Related Macular Degeneration | Completed | 2015-06-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02418754 | Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-R… | Phase2 | Neovascular Age-Related Macular Degeneration | Terminated | 2015-05-05 | 2017-04-03 | ClinicalTrials.gov |
| NCT02447276 | Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Phase2 | Osteoarthritis, Knee | Completed | 2015-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02392364 | Variable Interval Versus Set Interval Aflibercept for DME | Phase4 | Cystoid Macular Edema | Completed | 2015-04-15 | 2018-11-15 | ClinicalTrials.gov |
| NCT02396316 | Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients | Phase3 | Glaucoma, Neovascular | Completed | 2015-04-02 | 2016-09-06 | ClinicalTrials.gov |
| NCT02265952 | Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia… | Phase2 | Homozygous Familial Hypercholesterolemia | Completed | 2015-02-04 | 2018-07-23 | ClinicalTrials.gov |
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients Wi… | Phase1 | Non-Hodgkin Lymphoma | Completed | 2015-01-09 | 2025-08-21 | ClinicalTrials.gov |
| NCT02171416 | Cold Contact Urticaria Treatment With Rilonacept | Phase2 | Cold Contact Urticaria | Completed | 2015-01-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02305238 | Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macul… | Phase4 | Wet Macular Degeneration | Completed | 2014-12-19 | 2017-12-20 | ClinicalTrials.gov |
| NCT02260687 | Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization | — | Choroidal Neovascularization | Completed | 2014-12-05 | 2018-08-22 | ClinicalTrials.gov |
| NCT02299336 | Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subj… | Phase4 | Diabetic Macular Edema | Completed | 2014-11-24 | 2017-01-09 | ClinicalTrials.gov |
| NCT01997164 | Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either N… | Phase1 | Neovascular Age-Related Macular Degeneration | Completed | 2014-11-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02297204 | The Endurance 1 Trial | Phase4 | Diabetic Macular Edema | Completed | 2014-11-01 | 2018-03-19 | ClinicalTrials.gov |
| NCT02127801 | Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmaco… | Phase1 | Allergy | Completed | 2014-10-31 | 2015-12-31 | ClinicalTrials.gov |
| NCT02284425 | Study of REGN1193 in Patients With Type 2 Diabetes Mellitus | Phase1 | Diabetes Mellitus, Type 2 | Terminated | 2014-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02204683 | Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Ag… | Phase1 | Neovascular Macular Degeneration | Completed | 2014-09-05 | 2016-12-14 | ClinicalTrials.gov |
| NCT02120950 | Aflibercept in Polypoidal Choroidal Vasculopathy | Phase4 | Neovascular Macular Degeneration | Completed | 2014-05-29 | 2017-07-07 | ClinicalTrials.gov |
| NCT02121080 | Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Vo… | Phase1 | Healthy Volunteers | Completed | 2014-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01783925 | Eylea Post Marketing Surveillance(PMS) | — | Macular Degeneration | Completed | 2014-04-29 | 2018-12-31 | ClinicalTrials.gov |
| NCT02107872 | Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN… | Phase1 | Metabolic Disorders | Completed | 2014-04-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02689518 | EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection | Phase4 | Macular Degeneration | Completed | 2014-04-01 | 2019-11-12 | ClinicalTrials.gov |
| NCT02092532 | Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIV… | Phase4 | Neovascular Polypoidal Choroidal Vasculopathy | Unknown | 2014-03-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02061865 | Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Yea… | Phase1 | Neovascular Wet Age-related Macular Degeneration (AMD) | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02040220 | Prospective, Non-interventional, Multi-center Post-authorization Safety Study o… | — | Retinal Vein Occlusion | Completed | 2014-01-24 | 2018-11-09 | ClinicalTrials.gov |
| NCT02279537 | Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD | — | Wet Macular Degeneration | Completed | 2014-01-02 | 2019-04-17 | ClinicalTrials.gov |
| NCT01988246 | Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Ca… | Phase1 | Diabetic Retinopathy | Completed | 2013-12-01 | 2020-01-14 | ClinicalTrials.gov |
| NCT01909791 | Treatment for CI-DME in Eyes With Very Good VA Study | Phase3 | Diabetic Macular Edema | Completed | 2013-10-01 | 2018-09-11 | ClinicalTrials.gov |
| NCT01922661 | Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics o… | Phase1 | Allergy | Completed | 2013-08-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01933763 | An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REG… | Phase1 | Healthy Volunteers | Completed | 2013-08-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01914380 | Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macul… | — | Wet Age-related Macular Degeneration | Completed | 2013-07-29 | 2017-03-31 | ClinicalTrials.gov |
| NCT01857544 | Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macu… | Phase4 | Retinal Vein Occlusion | Unknown | 2013-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01893528 | Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN20… | Phase1 | Healthy Volunteers | Completed | 2013-06-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01870427 | NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated W… | Phase4 | Macular Edema With Central Retinal Vein Occlusions | Completed | 2013-06-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01868360 | Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea | Phase1 | Corneal Neovascularization | Terminated | 2013-06-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01871376 | Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With H… | Phase4 | Polypoidal Choroidal Vasculopathy | Completed | 2013-05-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01771081 | Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema … | — | Ophthalmology | Completed | 2013-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01813773 | Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Re… | Phase2 | Proliferative Diabetic Retinopathy | Completed | 2013-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01783886 | Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Centr… | Phase3 | Macular Edema | Completed | 2013-02-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01773954 | Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular… | Na | Age-Related Macular Degeneration | Completed | 2013-02-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01756248 | EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Jap… | — | Macular Degeneration | Completed | 2012-12-26 | 2019-05-20 | ClinicalTrials.gov |
| NCT01756261 | EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketin… | — | Macular Degeneration | Completed | 2012-12-26 | 2017-02-27 | ClinicalTrials.gov |
| NCT01749878 | Study to Assess the Safety and Tolerability of Single Doses of REGN1500 | Phase1 | Hypertriglyceridemia | Completed | 2012-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01722656 | Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized… | Phase4 | Submacular Vascularized Pigment Epithelial Detachments | Completed | 2012-11-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01579760 | Intravitreal Aflibercept Injection for Radiation Retinopathy | Phase1 | Radiation Retinopathy | Completed | 2012-11-01 | 2019-03-27 | ClinicalTrials.gov |
| NCT01722045 | Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascula… | Phase4 | Age - Related Macular Degeneration (AMD) | Completed | 2012-11-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01710332 | The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Pe… | Phase2 | Central Serous Chorioretinopathy | Completed | 2012-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01727869 | Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patie… | Phase1 | Cancer | Completed | 2012-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01627249 | Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and R… | Phase3 | Diabetic Macular Edema | Completed | 2012-08-01 | 2019-04-18 | ClinicalTrials.gov |
| NCT01670162 | On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Pe… | Phase4 | Age Related Macular Degeneration | Unknown | 2012-08-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01617148 | Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Afliber… | Phase4 | Exudative Macular Degeneration | Completed | 2012-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01605708 | Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refrac… | Phase1 | Pruritus | Terminated | 2012-06-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01521559 | Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept In… | Phase3 | Branch Retinal Vein Occlusion | Completed | 2012-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01540539 | Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2012-03-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01543568 | Study for Recalcitrant Age Related Macular Degeneration | Phase4 | Age Related Macular Degeneration | Completed | 2012-02-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01512966 | Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema) | Phase3 | Macular Edema | Completed | 2012-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01482910 | VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With We… | Phase3 | Macular Degeneration | Completed | 2011-12-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01495208 | Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED)… | Phase4 | Fibrovascular Pigment Epithelial Detachment | Withdrawn | 2011-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01459796 | Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prev… | Phase3 | Gout | Terminated | 2011-11-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01451645 | Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the … | Phase4 | Intercritical Gout | Completed | 2011-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01331681 | Intravitreal Aflibercept Injection in Vision Impairment Due to DME | Phase3 | Diabetes Mellitus | Completed | 2011-05-09 | 2015-03-30 | ClinicalTrials.gov |
| NCT01363440 | Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patien… | Phase3 | Diabetic Macular Edema | Completed | 2011-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01249664 | VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (m… | Phase3 | Myopia, Pathological | Completed | 2010-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01187563 | A Study of Tocilizumab in Patients With Rheumatoid Arthritis | — | Rheumatoid Arthritis | Completed | 2010-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01001923 | Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis … | Phase2 | Abdominal Pain Upper | Terminated | 2009-12-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00964795 | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; … | Phase3 | Neovascular Age-related Macular Degeneration | Completed | 2009-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01001715 | Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain | Phase2 | Back Pain | Terminated | 2009-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01012973 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy a… | Phase3 | Retinal Vein Occlusion | Completed | 2009-10-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00944892 | A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteo… | Phase1 | Osteoarthritis of the Knee | Completed | 2009-08-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00943072 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy a… | Phase3 | Macular Edema Secondary to Central Retinal Vein Occlusion | Completed | 2009-07-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00958438 | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-… | Phase3 | Gout | Completed | 2009-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00921661 | Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patien… | Phase1 | Colorectal Neoplasms | Completed | 2009-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00871559 | A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR15… | Phase1 | Advanced Solid Malignancies | Completed | 2009-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT00876044 | A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patien… | Phase1 | Cancer | Completed | 2009-04-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00856206 | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) | Phase3 | Gout | Completed | 2009-03-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00855920 | Study Utilizing Rilonacept in Gout Exacerbations | Phase3 | Acute Gout Flare | Completed | 2009-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00856310 | A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Hea… | Phase1 | Healthy | Completed | 2009-02-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00829829 | PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 | Phase3 | Intercritical Gout | Completed | 2009-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00789477 | DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-532… | Phase2 | Diabetic Macular Edema | Completed | 2008-12-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplati… | Phase1 | Advanced Carcinoma | Terminated | 2008-11-30 | 2011-06-30 | ClinicalTrials.gov |
| NCT00637377 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy a… | Phase3 | Macular Degeneration | Completed | 2008-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00644124 | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-c… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 2008-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Ge… | Phase3 | Pancreatic Neoplasm | Terminated | 2007-12-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00561470 | Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treat… | Phase3 | Colorectal Neoplasms | Completed | 2007-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00610363 | Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout … | Phase2 | Gout | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00545246 | A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Jap… | Phase1 | Neoplasms | Completed | 2007-10-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00532155 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel fo… | Phase3 | Carcinoma | Completed | 2007-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00509795 | Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and … | Phase3 | Macular Degeneration | Completed | 2007-08-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00527423 | Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Tra… | Phase2 | Macular Degeneration | Completed | 2007-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Pr… | Phase3 | Prostatic Neoplasms | Completed | 2007-08-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00479076 | A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese … | Phase1 | Neoplasms | Completed | 2007-03-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00396591 | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | Phase2 | Ovarian Neoplasms | Completed | 2006-10-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00383370 | Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With… | Phase1 | Neovascular Age Related Macular Degeneration | Completed | 2006-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00381121 | University of Michigan "Nephrology Research BioBank" | — | Chronic Kidney Disease | Recruiting | 2006-09-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT00327444 | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Canc… | Phase2 | Ovarian Neoplasms | Completed | 2006-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian C… | Phase2 | Neoplasms | Completed | 2006-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00320788 | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothe… | Phase2 | Macular Degeneration | Completed | 2006-04-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00320814 | Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema | Phase1 | Diabetic Macular Edema | Completed | 2006-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00284141 | Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Er… | Phase2 | Pulmonary Diseases | Completed | 2006-01-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00288704 | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) | Phase3 | Familial Cold Autoinflammatory Syndrome (FCAS) | Completed | 2005-12-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01803321 | Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Ped… | Phase1 | Systemic Juvenile Idiopathic Arthritis | Completed | 2005-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00320775 | Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patie… | Phase1 | Macular Degeneration | Completed | 2005-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00083213 | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced… | Phase1 | Cancer | Completed | 2004-01-01 | — | ClinicalTrials.gov |
| NCT00082823 | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced… | Phase1 | Cancer | Completed | 2004-01-01 | — | ClinicalTrials.gov |
| NCT00045266 | VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma | Phase1 | Lymphoma | Completed | 2002-04-01 | — | ClinicalTrials.gov |
| NCT00036946 | VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-… | Phase1 | Lymphoma | Completed | 2001-11-01 | — | ClinicalTrials.gov |
| NCT00707694 | The Longevity Genes in Founder Populations Project | — | Extreme Longevity | Recruiting | 1998-07-01 | 2032-12-01 | ClinicalTrials.gov |
Total clinical trials: 508
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| GCSF | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Bevacizumab | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Chemotherapy | Drug | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Ubamatamab | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | RECRUITING | NCT03972657 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | RECRUITING | NCT03972657 |
| Placebo | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| ALN-CFB | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemiplimab | Other | Phase PHASE2 | Solid Tumors | RECRUITING | NCT06651593 |
| SAR444881 | Other | Phase PHASE2 | Solid Tumors | RECRUITING | NCT06651593 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Odronextamab | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| Vonsetamig | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| REGN17372+Linvoseltamab | Other | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07455851 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07455851 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Linvoseltamab | Other | Phase PHASE2 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | RECRUITING | NCT06140524 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Alirocumab | Other | Phase PHASE2 | Hypercholesterolemia | RECRUITING | NCT07477704 |
| Cemiplimab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04291105 |
| VV1 | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04291105 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Non-interventional | Other | Preclinical | Long Term Safety Following GM T Cell Therapy | RECRUITING | NCT06798298 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGN7075 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Platinum-based chemotherapy | Drug | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Cemiplimab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Daratumumab | Other | Phase PHASE3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | RECRUITING | NCT07393282 |
| Linvoseltamab | Other | Phase PHASE3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | RECRUITING | NCT07393282 |
| Pozelimab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Cemdisiran | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Pozelimab + Cemdisiran | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Cevostamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Cemiplimab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Fianlimab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Isatuximab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | RECRUITING | NCT07594093 |
| Cemiplimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06931717 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07685808 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07685808 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Trifluridine-tipiracil | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04626635 |
| Bevacizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04626635 |
| Platinum-based doublet chemotherapy | Drug | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04626635 |
| Cemiplimab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04626635 |
| REGN7075 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04626635 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Capecitabine | Other | Phase PHASE1 | Hormone Receptor-positive Breast Cancer | COMPLETED | NCT05064085 |
| Cemiplimab | Other | Phase PHASE1 | Hormone Receptor-positive Breast Cancer | COMPLETED | NCT05064085 |
| Placebo | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05785767 |
| cemiplimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05785767 |
| fianlimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05785767 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Placebo | Other | Phase PHASE2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | ACTIVE_NOT_RECRUITING | NCT06421636 |
| REGN7999 | Other | Phase PHASE2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | ACTIVE_NOT_RECRUITING | NCT06421636 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| Dupilumab | Other | Phase PHASE2 | Eosinophilic Gastritis (EoG) | ACTIVE_NOT_RECRUITING | NCT05831176 |
| Alirocumab | Other | Phase PHASE2 | Hypercholesterolemia | RECRUITING | NCT07477704 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | NOT_YET_RECRUITING | NCT07675811 |
| Mevonlerbart | Other | Phase PHASE3 | Allergic Conjunctivitis | NOT_YET_RECRUITING | NCT07675811 |
| Freneslerbart | Other | Phase PHASE3 | Allergic Conjunctivitis | NOT_YET_RECRUITING | NCT07675811 |
| REGN-2Cat | Other | Phase PHASE3 | Allergic Conjunctivitis | NOT_YET_RECRUITING | NCT07675811 |
| REGN22530 | Other | Phase PHASE1 | Primary Open Angle Glaucoma (POAG) | NOT_YET_RECRUITING | NCT07675824 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT07543055 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | ACTIVE_NOT_RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | ACTIVE_NOT_RECRUITING | NCT06369467 |
| Dupilumab | Other | Preclinical | Food Allergy | AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | RECRUITING | NCT07527910 |
| Tirzepatide | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | RECRUITING | NCT07527910 |
| ALN-PNP | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | RECRUITING | NCT07527910 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| cemiplimab | Other | Phase PHASE3 | Carcinoma，Non-Small-Cell Lung | COMPLETED | NCT03088540 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma，Non-Small-Cell Lung | COMPLETED | NCT03088540 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma，Non-Small-Cell Lung | COMPLETED | NCT03088540 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma，Non-Small-Cell Lung | COMPLETED | NCT03088540 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma，Non-Small-Cell Lung | COMPLETED | NCT03088540 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma，Non-Small-Cell Lung | COMPLETED | NCT03088540 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07527923 |
| REGN20423 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07527923 |
| Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | RECRUITING | NCT03972657 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | RECRUITING | NCT03972657 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | ACTIVE_NOT_RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | ACTIVE_NOT_RECRUITING | NCT06369467 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Noninterventional | Other | Preclinical | Chronic Kidney Disease (CKD) | RECRUITING | NCT05106387 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| Placebo (PB) | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| Diluent | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| ALN-SOD | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. | Other | Phase PHASE2 | Merkel Cell Carcinoma, Stage I | RECRUITING | NCT07387198 |
| Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles | Other | Phase PHASE2 | Merkel Cell Carcinoma, Stage I | RECRUITING | NCT07387198 |
| REGN7945+Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT06669247 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT06669247 |
| REGN7257 | Other | Phase PHASE1 | Severe Aplastic Anemia (SAA) | TERMINATED | NCT04409080 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06931717 |
| Cemiplimab | Other | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT03294083 |
| Pexastimogene Devacirepvec (Pexa-Vec) | Other | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT03294083 |
| REGN17372+Linvoseltamab | Other | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07455851 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07455851 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma (MM) | WITHDRAWN | NCT07428369 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma (MM) | WITHDRAWN | NCT07428369 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma (MM) | WITHDRAWN | NCT07428369 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma (MM) | WITHDRAWN | NCT07428369 |
| Linvoseltamab | Other | Phase PHASE2 | Multiple Myeloma (MM) | WITHDRAWN | NCT07428369 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05744921 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05744921 |
| Cemiplimab | Other | Phase PHASE2 | SMARCB1-Deficient Malignancies | RECRUITING | NCT06444880 |
| Ubamatamab | Other | Phase PHASE2 | SMARCB1-Deficient Malignancies | RECRUITING | NCT06444880 |
| dupilumab | Other | Preclinical | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT06693531 |
| Placebo | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| ALN-CFB | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Oral corticosteroids (OCS) | Other | Phase PHASE2 | Bullous Pemphigoid | COMPLETED | NCT04206553 |
| Matching Placebo | Other | Phase PHASE2 | Bullous Pemphigoid | COMPLETED | NCT04206553 |
| dupilumab | Other | Phase PHASE2 | Bullous Pemphigoid | COMPLETED | NCT04206553 |
| Fianlimab+cemiplimab | Other | Phase PHASE2 | Melanoma | ENROLLING_BY_INVITATION | NCT06848088 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Placebo | Other | Phase PHASE2 | Alopecia Areata | RECRUITING | NCT05551793 |
| Dupilumab | Other | Phase PHASE2 | Alopecia Areata | RECRUITING | NCT05551793 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Odronextamab | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| Vonsetamig | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| REGN5093 | Other | Phase PHASE1 | NSCLC | RECRUITING | NCT04077099 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | ACTIVE_NOT_RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | ACTIVE_NOT_RECRUITING | NCT07431086 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Fianlimab | Other | Phase PHASE1 | Nasopharyngeal Carcinoma | NOT_YET_RECRUITING | NCT07650266 |
| Cemiplimab | Other | Phase PHASE1 | Nasopharyngeal Carcinoma | NOT_YET_RECRUITING | NCT07650266 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Asthma, Allergic | ACTIVE_NOT_RECRUITING | NCT05720325 |
| House Dust Mites (HDM) | Other | Phase PHASE2 | Asthma, Allergic | ACTIVE_NOT_RECRUITING | NCT05720325 |
| Dupilumab | Other | Phase PHASE2 | Asthma, Allergic | ACTIVE_NOT_RECRUITING | NCT05720325 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| High-dose REGN4461 | Other | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Low-Dose REGN4461 | Other | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Placebo | Other | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Linvoseltamab | Other | Phase PHASE2 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | RECRUITING | NCT06140524 |
| Nivolumab | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT04695977 |
| CMP-001 | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT04695977 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| GCSF | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Bevacizumab | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Chemotherapy | Drug | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Ubamatamab | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07637851 |
| Cemiplimab-Rwlc | Other | Phase PHASE2 | Non-small Cell Lung Cancer Stage III | RECRUITING | NCT06449313 |
| Daratumumab | Other | Phase PHASE3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | RECRUITING | NCT07393282 |
| Linvoseltamab | Other | Phase PHASE3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | RECRUITING | NCT07393282 |
| Fianlimab | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Biopsy | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Biospecimen Collection | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Computed Tomography | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Cemiplimab | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | SUSPENDED | NCT05929664 |
| Alirocumab | Other | Phase PHASE2 | Hypercholesterolemia | RECRUITING | NCT07477704 |
| cemiplimab | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT04916002 |
| vidutolimod | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT04916002 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab Plus Gemcitabine | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (mPDAC) | RECRUITING | NCT06790602 |
| Odronextamab | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| Vonsetamig | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | NOT_YET_RECRUITING | NCT07631637 |
| ALN-CIDEB | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | NOT_YET_RECRUITING | NCT07631637 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT07626411 |
| Apixaban | Other | Phase PHASE3 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT07626411 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT07626411 |
| DUPIXENT® | Other | Preclinical | Asthma | COMPLETED | NCT04287621 |
| Cemiplimab | Other | Phase PHASE2 | SMARCB1-Deficient Malignancies | RECRUITING | NCT06444880 |
| Ubamatamab | Other | Phase PHASE2 | SMARCB1-Deficient Malignancies | RECRUITING | NCT06444880 |
| Linvoseltamab | Other | Phase PHASE2 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | RECRUITING | NCT06140524 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Chemotherapy | Drug | Phase PHASE2 | Glioblastoma | NOT_YET_RECRUITING | NCT07620548 |
| Cemiplimab | Other | Phase PHASE2 | Glioblastoma | NOT_YET_RECRUITING | NCT07620548 |
| NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy | Drug | Phase PHASE2 | Glioblastoma | NOT_YET_RECRUITING | NCT07620548 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | ACTIVE_NOT_RECRUITING | NCT05092347 |
| odronextamab | Other | Phase PHASE1 | Relapsed/Refractory Aggressive B-Cell Lymphoma | COMPLETED | NCT02651662 |
| cemiplimab | Other | Phase PHASE1 | Relapsed/Refractory Aggressive B-Cell Lymphoma | COMPLETED | NCT02651662 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Cemiplimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06931717 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Dupilumab | Other | Phase PHASE3 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT02612454 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07493304 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07493304 |
| Placebo | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Cisplatin | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Carboplatin | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Paclitaxel | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Pemetrexed | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Cemiplimab | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Fianlimab | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| aflibercept 8 mg PFS | Other | Phase PHASE3 | Diabetic Macular Edema (DME) | COMPLETED | NCT05989126 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Tocilizumab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Linvoseltamab | Other | Phase PHASE4 | Relapsed/Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07609940 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Topical emollient (moisturizer) | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| dupilumab | Other | Phase PHASE4 | Moderate-to-Severe Atopic Dermatitis | COMPLETED | NCT05590585 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Merkel Cell Carcinoma | RECRUITING | NCT04975152 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| ICS/LABA | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Matching Placebo | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| dupilumab | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Health Surveys | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| ICS/LABA | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Matching Placebo | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| dupilumab | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Health Surveys | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| ICS/LABA | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Matching Placebo | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| dupilumab | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Health Surveys | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| ICS/LABA | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Matching Placebo | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| dupilumab | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Health Surveys | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | RECRUITING | NCT07318610 |
| ICS/LABA | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Matching Placebo | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| dupilumab | Other | Phase PHASE4 | Asthma | ACTIVE_NOT_RECRUITING | NCT06572228 |
| Health Surveys | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| PB | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | COMPLETED | NCT06608901 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| dupilumab | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT07112378 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| Chemotherapy | Drug | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810/chemo/ipi | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN2810 | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT03409614 |
| REGN15505+REGN4336 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505+Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| REGN15505 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | NCT07594106 |
| Placebo | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| REGN20934 | Other | Phase PHASE1 | Overweight or Obesity | NOT_YET_RECRUITING | NCT07594093 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | RECRUITING | NCT07058012 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | RECRUITING | NCT06091865 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| dupilumab | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | NOT_YET_RECRUITING | NCT07587658 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Dupilumab | Other | Preclinical | Food Allergy | TEMPORARILY_NOT_AVAILABLE | NCT06631677 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT06230224 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1909 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1908 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Matching Placebo-Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Platinum-doublet chemotherapy | Drug | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN2810 | Other | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN846 | Other | Phase PHASE1 | Pruritus | TERMINATED | NCT01605708 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1909 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1908 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Matching Placebo-Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Platinum-doublet chemotherapy | Drug | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN2810 | Other | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1909 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1908 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Matching Placebo-Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Platinum-doublet chemotherapy | Drug | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN2810 | Other | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1909 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1908 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Matching Placebo-Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Platinum-doublet chemotherapy | Drug | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN2810 | Other | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Matching Placebo-Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Platinum-doublet chemotherapy | Drug | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN2810 | Other | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Cemiplimab | Other | Phase PHASE1 | High-Grade Glioma (HGG) | NOT_YET_RECRUITING | NCT07567469 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | ACTIVE_NOT_RECRUITING | NCT05961709 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | ACTIVE_NOT_RECRUITING | NCT06593600 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Macular Degeneration | COMPLETED | NCT01756261 |
| Placebo | Other | Phase PHASE2 | Cold Contact Urticaria | COMPLETED | NCT02171416 |
| Rilonacept | Other | Phase PHASE2 | Cold Contact Urticaria | COMPLETED | NCT02171416 |
| Aflibercept | Other | Phase PHASE4 | Exudative Macular Degeneration | COMPLETED | NCT01617148 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT02712008 |
| REGN910-3 | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT02712008 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Eye Diseases | COMPLETED | NCT02811692 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Choroidal Neovascularization | COMPLETED | NCT02260687 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03645746 |
| REGN5069 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03645746 |
| Topical IOP-lowering drugs | Drug | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT03639675 |
| Aflibercept (EYLEA, BAY86-5321) | Other | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT03639675 |
| Cemiplimab | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT03580694 |
| REGN4659 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT03580694 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | TERMINATED | NCT04616105 |
| REGN6490 | Other | Phase PHASE1 | Healthy Volunteer | TERMINATED | NCT04616105 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | TERMINATED | NCT04616079 |
| REGN6490 | Other | Phase PHASE1 | Healthy Volunteer | TERMINATED | NCT04616079 |
| Dupilumab | Other | Preclinical | Type 2 Inflammatory Disorders | APPROVED_FOR_MARKETING | NCT04776694 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05102136 |
| REGN9933 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05102136 |
| Matching placebo | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04203797 |
| dupilumab | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04203797 |
| Surveys | Other | Preclinical | Post-acute COVID-19 (PACS), or "long COVID" Syndrome | COMPLETED | NCT05013723 |
| evinacumab | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT03409744 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE4 | Diabetic Macular Edema (DME) | RECRUITING | NCT06662994 |
| Platinum-doublet chemotherapy | Drug | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| REGN2810 | Other | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Cemdisiran | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04888507 |
| Pozelimab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04888507 |
| ISA101b | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT04646005 |
| Cemiplimab | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT04646005 |
| Placebo | Other | Phase PHASE1 | Systemic Juvenile Idiopathic Arthritis | COMPLETED | NCT01803321 |
| rilonacept (IL-1 Trap) | Other | Phase PHASE1 | Systemic Juvenile Idiopathic Arthritis | COMPLETED | NCT01803321 |
| Placebo (for REGN475/SAR164877) | Other | Phase PHASE2 | Abdominal Pain Upper | TERMINATED | NCT01001923 |
| REGN475/SAR164877 | Other | Phase PHASE2 | Abdominal Pain Upper | TERMINATED | NCT01001923 |
| Placebo (for REGN475/SAR164877) | Other | Phase PHASE2 | Back Pain | TERMINATED | NCT01001715 |
| REGN475/SAR164877 | Other | Phase PHASE2 | Back Pain | TERMINATED | NCT01001715 |
| REGN1154 or placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01540539 |
| No Drug | Drug | Phase PHASE3 | Myopia, Pathological | COMPLETED | NCT01249664 |
| VEGF Trap-Eye (BAY86-5321) | Other | Phase PHASE3 | Myopia, Pathological | COMPLETED | NCT01249664 |
| allopurinol | Other | Phase PHASE4 | Intercritical Gout | COMPLETED | NCT01451645 |
| placebo | Other | Phase PHASE4 | Intercritical Gout | COMPLETED | NCT01451645 |
| Colchicine (Colcrys®) | Other | Phase PHASE4 | Intercritical Gout | COMPLETED | NCT01451645 |
| placebo | Other | Phase PHASE1 | Allergy | COMPLETED | NCT01922661 |
| REGN1908-1909 | Other | Phase PHASE1 | Allergy | COMPLETED | NCT01922661 |
| VEGF Trap-Eye (BAY86-5321) | Other | Phase PHASE3 | Macular Edema | COMPLETED | NCT01512966 |
| Rescue Therapy with PDT, Laser or Intravitreal Steroids | Drug | Phase PHASE4 | Neovascular Polypoidal Choroidal Vasculopathy | UNKNOWN | NCT02092532 |
| Rescue Intravitreal Aflibercept Injection | Other | Phase PHASE4 | Neovascular Polypoidal Choroidal Vasculopathy | UNKNOWN | NCT02092532 |
| Aflibercept | Other | Phase PHASE4 | Retinal Vein Occlusion | UNKNOWN | NCT01857544 |
| Aflibercept | Other | Phase PHASE4 | Age Related Macular Degeneration | UNKNOWN | NCT01670162 |
| Sham treatment | Drug | Phase PHASE3 | Retinal Vein Occlusion | COMPLETED | NCT01012973 |
| Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE3 | Retinal Vein Occlusion | COMPLETED | NCT01012973 |
| placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01893528 |
| REGN2009 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01893528 |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Other | Phase PHASE3 | Branch Retinal Vein Occlusion | COMPLETED | NCT01521559 |
| Macular Laser Photocoagulation | Other | Phase PHASE3 | Branch Retinal Vein Occlusion | COMPLETED | NCT01521559 |
| REGN2176-3 | Other | Phase PHASE1 | Neovascular Wet Age-related Macular Degeneration (AMD) | COMPLETED | NCT02061865 |
| placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02121080 |
| REGN2222(SAR438584) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02121080 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01933763 |
| REGN1193 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01933763 |
| Cetuximab | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01727869 |
| Erlotinib | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01727869 |
| REGN1400 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01727869 |
| placebo | Other | Phase PHASE1 | Metabolic Disorders | COMPLETED | NCT02107872 |
| REGN1500 | Other | Phase PHASE1 | Metabolic Disorders | COMPLETED | NCT02107872 |
| Placebo: Standard of care only | Other | Phase PHASE1 | Corneal Neovascularization | TERMINATED | NCT01868360 |
| Subconjunctival aflibercept | Other | Phase PHASE1 | Corneal Neovascularization | TERMINATED | NCT01868360 |
| Ranibizumab (or other DME treatment) | Drug | Preclinical | Ophthalmology | COMPLETED | NCT01771081 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT01997164 |
| REGN910 | Other | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT01997164 |
| REGN910-3 | Other | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT01997164 |
| Aflibercept | Other | Phase PHASE4 | Submacular Vascularized Pigment Epithelial Detachments | COMPLETED | NCT01722656 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02516618 |
| Fasinumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02516618 |
| Placebo | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT02284425 |
| REGN1193 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT02284425 |
| Macular Laser Photocoagulation | Other | Phase PHASE3 | Macular Edema | COMPLETED | NCT01783886 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE3 | Macular Edema | COMPLETED | NCT01783886 |
| placebo | Other | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT01749878 |
| REGN1500 | Other | Phase PHASE1 | Hypertriglyceridemia | COMPLETED | NCT01749878 |
| Macular Laser Photocoagulation | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01363440 |
| Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01363440 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE2 | Proliferative Diabetic Retinopathy | COMPLETED | NCT01813773 |
| REGN1033 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02741739 |
| REGN2222 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02828397 |
| Visudyne | Other | Phase PHASE3 | Macular Degeneration | COMPLETED | NCT01482910 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE3 | Macular Degeneration | COMPLETED | NCT01482910 |
| REGN2810 | Other | Phase PHASE1 | Advanced Malignancies | WITHDRAWN | NCT02520245 |
| Intravitreal aflibercept injection 2.0mg | Other | Phase PHASE4 | Polypoidal Choroidal Vasculopathy | COMPLETED | NCT01871376 |
| Aflibercept (2.0 mg) | Other | Phase PHASE4 | Macular Edema With Central Retinal Vein Occlusions | COMPLETED | NCT01870427 |
| aflibercept 2.0 mg | Other | Phase PHASE4 | Age Related Macular Degeneration | COMPLETED | NCT01543568 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02870400 |
| REGN2477 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02870400 |
| Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Age-related Macular Degeneration (AMD) | COMPLETED | NCT02585401 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT02447276 |
| REGN475 | Other | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT02447276 |
| Intravitreal Aflibercept Injection | Other | Phase PHASE2 | Central Serous Chorioretinopathy | COMPLETED | NCT01710332 |
| Allopurinol | Other | Phase PHASE3 | Gout | TERMINATED | NCT01459796 |
| Placebo | Other | Phase PHASE3 | Gout | TERMINATED | NCT01459796 |
| Rilonacept | Other | Phase PHASE3 | Gout | TERMINATED | NCT01459796 |
| Aflibercept | Other | Preclinical | Retinal Hemangioma | NO_LONGER_AVAILABLE | NCT01714115 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Wet Macular Degeneration | COMPLETED | NCT02541084 |
| Rilonacept | Other | Phase EARLY_PHASE1 | Autoimmune Neurosensory Hearing Loss (ANSHL) | UNKNOWN | NCT02828033 |
| Sham Injection | Other | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT02396316 |
| Aflibercept (Eylea, BAY 86-5321) | Other | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT02396316 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE4 | Age - Related Macular Degeneration (AMD) | COMPLETED | NCT01722045 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02777151 |
| REGN3470-3471-3479 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02777151 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Wet Age-related Macular Degeneration | COMPLETED | NCT01914380 |
| Intravitreal Aflibercept Injection 2mg | Other | Phase PHASE4 | Neovascular Age-related Macular Degeneration | UNKNOWN | NCT03468296 |
| Intravitreal Aflibercept Injection | Other | Approved | Age-Related Macular Degeneration | COMPLETED | NCT01773954 |
| Intravitreal Aflibercept | Other | Phase PHASE4 | Diabetic Macular Edema | WITHDRAWN | NCT03059277 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03146416 |
| Evinacumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03146416 |
| Aflibercept (EYLEA, BAY-86-5321) | Other | Preclinical | Wet Macular Degeneration | COMPLETED | NCT02321241 |
| Aflibercept | Other | Phase PHASE4 | Fibrovascular Pigment Epithelial Detachment | WITHDRAWN | NCT01495208 |
| Aflibercept (Eylea, BAY86-5321) | Other | Preclinical | Retinal Vein Occlusion | COMPLETED | NCT02645747 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03115996 |
| REGN3918 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03115996 |
| Aflibercept (Eylea, BAY86-5321) | Other | Preclinical | Wet Macular Degeneration | COMPLETED | NCT03278262 |
| Suptavumab 30 mg/kg - 2 Doses | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Suptavumab 30 mg/kg- 1 Dose | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Placebo Matched to Suptavumab | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Suptavumab 30 mg/kg | Other | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Intravitreal Aflibercept Injection | Other | Phase PHASE4 | Cystoid Macular Edema | COMPLETED | NCT02392364 |
| aflibercept 2.0 mg | Other | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02297204 |
| Focal Laser Treatment | Drug | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02297204 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Wet Macular Degeneration | COMPLETED | NCT02540369 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Retinal Vein Occlusion | COMPLETED | NCT02040220 |
| Aflibercept monthly | Other | Phase PHASE1 | Radiation Retinopathy | COMPLETED | NCT01579760 |
| Aflibercept every 2 months | Other | Phase PHASE1 | Radiation Retinopathy | COMPLETED | NCT01579760 |
| Alirocumab | Other | Phase PHASE4 | Atherosclerosis | UNKNOWN | NCT02992301 |
| Matching placebo | Other | Phase PHASE2 | Sporadic Inclusion Body Myositis | WITHDRAWN | NCT03710941 |
| REGN2477+REGN1033 | Other | Phase PHASE2 | Sporadic Inclusion Body Myositis | WITHDRAWN | NCT03710941 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT02713204 |
| REGN910-3 | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT02713204 |
| Focal Laser | Other | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02299336 |
| Aflibercept | Other | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02299336 |
| Ezetimibe 10mg | Other | Phase PHASE4 | Myocardial Infarction | WITHDRAWN | NCT03750760 |
| Atorvastatin 80mg | Other | Phase PHASE4 | Myocardial Infarction | WITHDRAWN | NCT03750760 |
| Alirocumab | Other | Phase PHASE4 | Myocardial Infarction | WITHDRAWN | NCT03750760 |
| Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Macular Degeneration | COMPLETED | NCT03411941 |
| REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02265952 |
| Alirocumab 150 MG/ML [Praluent] | Other | Phase PHASE3 | Hemodialysis | UNKNOWN | NCT03480568 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03530514 |
| REGN4461 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03530514 |
| Placebo | Other | Phase EARLY_PHASE1 | Stroke | TERMINATED | NCT03507374 |
| Alirocumab | Other | Phase EARLY_PHASE1 | Stroke | TERMINATED | NCT03507374 |
| Matching placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03969849 |
| REGN5713-5714-5715 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03969849 |
| Sham | Other | Phase PHASE1 | Diabetic Retinopathy | COMPLETED | NCT01988246 |
| Aflibercept | Other | Phase PHASE1 | Diabetic Retinopathy | COMPLETED | NCT01988246 |
| placebo | Other | Phase PHASE2 | Low Back Pain | COMPLETED | NCT02620020 |
| Fasinumab | Other | Phase PHASE2 | Low Back Pain | COMPLETED | NCT02620020 |
| Sham | Other | Phase PHASE3 | Nonproliferative Diabetic Retinopathy | COMPLETED | NCT02718326 |
| Intravitreal aflibercept injection [IAI] | Other | Phase PHASE3 | Nonproliferative Diabetic Retinopathy | COMPLETED | NCT02718326 |
| Deferred aflibercept | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01909791 |
| Deferred laser | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01909791 |
| Prompt aflibercept | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01909791 |
| Prompt Laser | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01909791 |
| 0.3 mg intravitreal ranibizumab | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01627249 |
| 1.25 mg intravitreal bevacizumab | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01627249 |
| 2.0 mg intravitreal aflibercept | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01627249 |
| Dupilumab Only Product | Other | Phase PHASE4 | Atopic Dermatitis | UNKNOWN | NCT04520308 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration | TERMINATED | NCT02418754 |
| REGN2176-3 | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration | TERMINATED | NCT02418754 |
| Visudyne | Other | Phase PHASE4 | Neovascular Macular Degeneration | COMPLETED | NCT02120950 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE4 | Neovascular Macular Degeneration | COMPLETED | NCT02120950 |
| Aflibercept | Other | Phase PHASE2 | Radiation Retinopathy | UNKNOWN | NCT03085784 |
| placebo | Other | Phase PHASE1 | Allergy | COMPLETED | NCT02127801 |
| REGN1908-1909 | Other | Phase PHASE1 | Allergy | COMPLETED | NCT02127801 |
| Pozelimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04491838 |
| Intravitreal aflibercept injection | Other | Phase PHASE4 | Macular Degeneration | COMPLETED | NCT02689518 |
| Prompt Vitrectomy Plus Panretinal Photocoagulation | Other | Phase PHASE2 | Proliferative Diabetic Retinopathy | COMPLETED | NCT02858076 |
| 2-mg Intravitreous Aflibercept Injection | Other | Phase PHASE2 | Proliferative Diabetic Retinopathy | COMPLETED | NCT02858076 |
| Aflibercept | Other | Phase PHASE4 | Retinal Vein Occlusion | COMPLETED | NCT02503540 |
| Kinetics test | Other | Approved | Hypercholesterolemia, Familial | COMPLETED | NCT04722068 |
| Placebo | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT03399786 |
| evinacumab | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT03399786 |
| Aflibercept Injection | Other | Phase PHASE2 | Diabetic Retinopathy | COMPLETED | NCT03531294 |
| Aflibercept | Other | Phase PHASE2 | Proliferative Diabetic Retinopathy | COMPLETED | NCT02863354 |
| Matching Placebo | Other | Phase PHASE2 | Osteoarthritis of the Knee | TERMINATED | NCT03956550 |
| REGN5069 | Other | Phase PHASE2 | Osteoarthritis of the Knee | TERMINATED | NCT03956550 |
| Placebo | Other | Phase PHASE2 | Cat Allergy | COMPLETED | NCT03838731 |
| REGN1908-1909 | Other | Phase PHASE2 | Cat Allergy | COMPLETED | NCT03838731 |
| Sarilumab | Other | Phase PHASE1 | Morphea, Plaque Form | WITHDRAWN | NCT03679845 |
| Intravitreal Aflibercept Injection (IAI) | Other | Phase PHASE4 | Chorioretinal Vascular Disease | COMPLETED | NCT03767738 |
| Matching Placebo subcutaneous injection | Other | Phase PHASE4 | Saphenous Vein Graft Atherosclerosis | TERMINATED | NCT03542110 |
| Alirocumab 150 MG/ML subcutaneous injection | Other | Phase PHASE4 | Saphenous Vein Graft Atherosclerosis | TERMINATED | NCT03542110 |
| Dupilumab | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03886493 |
| garetosmab | Other | Phase PHASE3 | Fibrodyplasia Ossificans Progressiva (FOP) | WITHDRAWN | NCT04577820 |
| Cemdisiran | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04601844 |
| Pozelimab | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04601844 |
| optovue angiovue | Other | Phase PHASE4 | Wet Macular Degeneration | COMPLETED | NCT03022292 |
| Aflibercept Ophthalmic | Other | Phase PHASE4 | Wet Macular Degeneration | COMPLETED | NCT03022292 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04519437 |
| REGN10933+REGN10987 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04519437 |
| 89Zr˗DFO˗REGN3504 | Other | Phase PHASE1 | Advanced PD-L1 Positive Malignancies | TERMINATED | NCT03746704 |
| Alirocumab | Other | Phase PHASE3 | Coronary Vessel | COMPLETED | NCT03067844 |
| Placebo | Other | Phase PHASE1 | HIV Infections | TERMINATED | NCT03787095 |
| Cemiplimab | Other | Phase PHASE1 | HIV Infections | TERMINATED | NCT03787095 |
| Reflectance confocal microscopy | Other | Phase PHASE4 | Eczema | UNKNOWN | NCT05265234 |
| Optical Coherence Tomography | Other | Phase PHASE4 | Eczema | UNKNOWN | NCT05265234 |
| Dupilumab | Other | Phase PHASE4 | Eczema | UNKNOWN | NCT05265234 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04666441 |
| REGN10933+REGN10987 combination therapy | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04666441 |
| Casirivimab and Imdevimab Antibody Cocktail | Other | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT05157997 |
| Intravitreal Aflibercept | Other | Phase PHASE2 | Diabetic Macular Edema | WITHDRAWN | NCT04588948 |
| Laser photocoagulation | Other | Phase PHASE3 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT04004208 |
| Eylea (Aflibercept, BAY86-5321) | Other | Phase PHASE3 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT04004208 |
| Cemdisiran | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04940364 |
| Pozelimab | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04940364 |
| Radiation Therapy | Drug | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03438318 |
| Atezolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03438318 |
| CMP-001 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03438318 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT03084640 |
| CMP-001 | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT03084640 |
| Cemiplimab-Rwlc | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT04831450 |
| Atorvastatin | Other | Phase PHASE2 | Nephrotic Syndrome | TERMINATED | NCT03004001 |
| Alirocumab placebo | Other | Phase PHASE2 | Nephrotic Syndrome | TERMINATED | NCT03004001 |
| Alirocumab | Other | Phase PHASE2 | Nephrotic Syndrome | TERMINATED | NCT03004001 |
| Placebo | Other | Phase PHASE3 | Type2 Diabetes | COMPLETED | NCT03344692 |
| Alirocumab | Other | Phase PHASE3 | Type2 Diabetes | COMPLETED | NCT03344692 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT04709575 |
| REGN5715 | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT04709575 |
| REGN5714 | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT04709575 |
| REGN5713 | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT04709575 |
| Cemiplimab | Other | Phase PHASE1 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03294083 |
| Pexastimogene Devacirepvec (Pexa-Vec) | Other | Phase PHASE1 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03294083 |
| Cemiplimab-Rwlc | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | TERMINATED | NCT04242173 |
| Aflibercept (Eylea, BAY86-5321) | Other | Preclinical | Macular Edema | COMPLETED | NCT03161912 |
| Matching placebo | Other | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | COMPLETED | NCT03188666 |
| REGN2477 | Other | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | COMPLETED | NCT03188666 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04506645 |
| REGN5381 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04506645 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04426695 |
| REGN10933+REGN10987 combination therapy | Drug | Phase PHASE1 | COVID-19 | COMPLETED | NCT04426695 |
| Background Lipid Modifying Therapy (LMT) | Drug | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03175367 |
| Matching placebo | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03175367 |
| Evinacumab | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03175367 |
| Placebo | Other | Phase PHASE2 | Severe Hypertriglyceridemia (sHTG) | COMPLETED | NCT03452228 |
| evinacumab | Other | Phase PHASE2 | Severe Hypertriglyceridemia (sHTG) | COMPLETED | NCT03452228 |
| Matching Placebo (SC) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05293678 |
| REGN15160 (SC) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05293678 |
| Matching Placebo (IV) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05293678 |
| REGN15160 (IV) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05293678 |
| No Intervention | Other | Approved | Non-alcoholic Steatohepatitis (NASH) | TERMINATED | NCT05423327 |
| aflibercept | Other | Phase PHASE4 | Diabetic Retinopathy | COMPLETED | NCT02559180 |
| Placebo | Other | Phase PHASE3 | Healthy Participants | COMPLETED | NCT04452318 |
| REGN10933 + REGN10987 | Other | Phase PHASE3 | Healthy Participants | COMPLETED | NCT04452318 |
| rivaroxaban high dose | Other | Approved | Healthy Volunteer | COMPLETED | NCT05546957 |
| rivaroxaban low dose | Other | Approved | Healthy Volunteer | COMPLETED | NCT05546957 |
| Aspirin | Other | Approved | Healthy Volunteer | COMPLETED | NCT05546957 |
| Aflibercept (Eylea, BAY86-5321) | Other | Preclinical | Wet Age-related Macular Degeneration | COMPLETED | NCT03382587 |
| Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Macular Degeneration | COMPLETED | NCT01756248 |
| REGN3918 | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT04162470 |
| Deferred aflibercept | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Deferred laser | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Prompt aflibercept | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Prompt Sham | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| REGN3918 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03946748 |
| laser photocoagulation | Other | Phase PHASE3 | Retinopathy of Prematurity | COMPLETED | NCT04101721 |
| aflibercept | Other | Phase PHASE3 | Retinopathy of Prematurity | COMPLETED | NCT04101721 |
| Matching Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05505448 |
| REGN14284 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05505448 |
| PEG-IFN alfa-2a | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT05729139 |
| Cemiplimab-Rwlc | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT05729139 |
| High-dose aflibercept | Other | Phase PHASE2 | Neovascular (Wet) Age-Related Macular Degeneration | COMPLETED | NCT04126317 |
| aflibercept | Other | Phase PHASE2 | Neovascular (Wet) Age-Related Macular Degeneration | COMPLETED | NCT04126317 |
| Aflibercept | Other | Phase PHASE1 | Neovascular Macular Degeneration | COMPLETED | NCT02204683 |
| Cemiplimab | Other | Phase PHASE1 | Hepatitis B Virus | WITHDRAWN | NCT04046107 |
| REGN10933+REGN10987 combination therapy | Drug | Preclinical | COVID-19 | NO_LONGER_AVAILABLE | NCT04617535 |
| Non-Interventional | Other | Preclinical | Relapsed/Refractory Follicular Lymphoma | COMPLETED | NCT05338879 |
| Non-Interventional | Other | Preclinical | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT05338892 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Diabetic Retinopathy | COMPLETED | NCT02924311 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Wet Macular Degeneration | COMPLETED | NCT02279537 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Preclinical | Macular Degeneration | COMPLETED | NCT01783925 |
| Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE4 | Macular Degeneration | COMPLETED | NCT02581891 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Other | Phase PHASE4 | Wet Macular Degeneration | COMPLETED | NCT02305238 |
| Macular Laser Photocoagulation (Control) | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01331681 |
| VEGF Trap-Eye (BAY86-5321) | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01331681 |
| Non Applicable | Other | Preclinical | Intraocular Inflammation | COMPLETED | NCT05791695 |
| casirivimab+imdevimab combination therapy | Drug | Phase PHASE3 | COVID-19 | TERMINATED | NCT04425629 |
| Placebo | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Oropharynx | UNKNOWN | NCT03669718 |
| Cemiplimab | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Oropharynx | UNKNOWN | NCT03669718 |
| ISA101b | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Oropharynx | UNKNOWN | NCT03669718 |
| Dupilumab | Other | Phase PHASE4 | Atopic Dermatitis | COMPLETED | NCT03667014 |
| ISA101b | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Oropharynx | UNKNOWN | NCT04398524 |
| Hyperpolarized Xe129 | Other | Phase PHASE2 | Pulmonary Artery Hypertension | WITHDRAWN | NCT06122922 |
| Dupilumab | Other | Phase PHASE2 | Atopic Keratoconjunctivitis | UNKNOWN | NCT04296864 |
| Dupixent | Other | Phase PHASE4 | Atopic Dermatitis | RECRUITING | NCT05285839 |
| Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation | Procedure | Preclinical | Chronic Rhinosinusitis With Nasal Polyps | RECRUITING | NCT06129552 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05291546 |
| REGN5381 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05291546 |
| REGN9035 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05291546 |
| cemiplimab | Other | Phase PHASE1 | Malignancies | COMPLETED | NCT03005782 |
| REGN3767 | Other | Phase PHASE1 | Malignancies | COMPLETED | NCT03005782 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | TERMINATED | NCT04863014 |
| evinacumab | Other | Phase PHASE2 | Hypertriglyceridemia | TERMINATED | NCT04863014 |
| Matching Placebo | Other | Phase PHASE3 | Allergic Rhinitis Due to Cat Allergy | TERMINATED | NCT04981717 |
| REGN1908-1909 | Other | Phase PHASE3 | Allergic Rhinitis Due to Cat Allergy | TERMINATED | NCT04981717 |
| Gluten Powder | Other | Approved | Celiac Disease | COMPLETED | NCT04614571 |
| Evinacumab | Other | Phase PHASE3 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT04233918 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05481333 |
| REGN7999 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05481333 |
| fianlimab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT06384820 |
| cemiplimab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT06384820 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02943239 |
| REGN2477 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02943239 |
| REGN1033 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02943239 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05970718 |
| REGN7544 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05970718 |
| Matching Placebo (SC) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| Matching Placebo (IV) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| REGN7508 (SC) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| REGN7508 (IV) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| Aflibercept | Other | Phase PHASE1 | Irvine-Gass Syndrome | TERMINATED | NCT03396861 |
| Dupilumab | Other | Phase PHASE4 | Asthma | COMPLETED | NCT05036733 |
| Docetaxel | Other | Phase PHASE1 | Locally Advanced Head and Neck Squamous Cell Carcinoma | ENROLLING_BY_INVITATION | NCT05376553 |
| Cisplatin | Other | Phase PHASE1 | Locally Advanced Head and Neck Squamous Cell Carcinoma | ENROLLING_BY_INVITATION | NCT05376553 |
| Cemiplimab | Other | Phase PHASE1 | Locally Advanced Head and Neck Squamous Cell Carcinoma | ENROLLING_BY_INVITATION | NCT05376553 |
| Placebo | Other | Phase PHASE2 | Allergic Rhinitis | COMPLETED | NCT05430919 |
| REGN5715 | Other | Phase PHASE2 | Allergic Rhinitis | COMPLETED | NCT05430919 |
| REGN5714 | Other | Phase PHASE2 | Allergic Rhinitis | COMPLETED | NCT05430919 |
| REGN5713 | Other | Phase PHASE2 | Allergic Rhinitis | COMPLETED | NCT05430919 |
| aflibercept 8 mg | Other | Preclinical | Neovascular Age-related Macular Degeneration (nAMD) | WITHDRAWN | NCT06398080 |
| Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] | Other | Phase PHASE4 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT06665971 |
| Aflibercept Injection | Other | Phase PHASE4 | Diabetic Retinopathy | COMPLETED | NCT04708145 |
| RP1 | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04050436 |
| Cemiplimab | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04050436 |
| Dupilumab | Other | Preclinical | Food Allergy | NO_LONGER_AVAILABLE | NCT06631677 |
| Cemiplimab | Other | Phase PHASE1 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT04465487 |
| REGN6569 | Other | Phase PHASE1 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT04465487 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06137482 |
| REGN13335 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06137482 |
| Placebo | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT05469347 |
| Alirocumab | Other | Phase PHASE1 | Sepsis | COMPLETED | NCT05469347 |
| Cemiplimab | Other | Phase PHASE2 | Melanoma | RECRUITING | NCT04291105 |
| VV1 | Other | Phase PHASE2 | Melanoma | RECRUITING | NCT04291105 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05923424 |
| REGN17092 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05923424 |
| Dupilumab Prefilled Syringe | Other | Phase PHASE4 | Nasal Polyps | RECRUITING | NCT05094570 |
| Dupilumab Injectable Product | Other | Phase PHASE4 | Asthma | RECRUITING | NCT04380038 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT05131204 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT05131204 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT05131204 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT05131204 |
| Cemdisiran | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04811716 |
| Pozelimab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04811716 |
| Re-irradiation | Other | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| Conventional or hypofractionated | Other | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| cemiplimab (maintenance) | Other | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| cemiplimab (monotherapy) | Drug | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| Prednisone | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Sirolimus | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Everolimus | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Cemiplimab | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Non-Interventional | Other | Preclinical | Relapsed and Refractory Multiple Myeloma (RRMM) | COMPLETED | NCT05673967 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT03951831 |
| Leuprolide Acetate | Other | Phase PHASE2 | Prostate Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT03951831 |
| Degarelix | Other | Phase PHASE2 | Prostate Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT03951831 |
| REGN2810 | Other | Phase PHASE2 | Prostate Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT03951831 |
| Anti-PD-1 Monoclonal Antibody REGN2810 | Other | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Radical Prostatectomy | Other | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Ipilimumab | Other | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Pembrolizumab | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT04633278 |
| CMP-001 | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT04633278 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| cemiplimab | Other | Phase PHASE2 | Advanced Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT02760498 |
| REGN5459 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| aflibercept 8 mg PFS | Other | Phase PHASE3 | Diabetic Macular Edema (DME) | COMPLETED | NCT05989126 |
| Cemiplimab | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04706715 |
| 89Zr-DFO-REGN3767 | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04706715 |
| Matching Placebo | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT05353166 |
| REGN5381 | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT05353166 |
| Nab paclitaxel | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT04543071 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT04543071 |
| Cemiplimab | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT04543071 |
| Motixafortide | Other | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT04543071 |
| Non-Interventional | Other | Preclinical | Fibrodysplasia Ossificans Progressiva (FOP) | COMPLETED | NCT06064656 |
| Pembrolizumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02680184 |
| CMP-001 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02680184 |
| ctDNA testing | Other | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | Other | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | Other | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| Cemiplimab | Other | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| Rivaroxaban | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06444178 |
| REGN7508 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06444178 |
| REGN9933 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06444178 |
| Aspirin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06444178 |
| Placebo | Other | Phase PHASE2 | Alopecia Areata | RECRUITING | NCT05551793 |
| Dupilumab | Other | Phase PHASE2 | Alopecia Areata | RECRUITING | NCT05551793 |
| Placebo | Other | Phase PHASE1 | Nonalcoholic Fatty Liver Disease (NAFLD) | COMPLETED | NCT06024408 |
| ALN-PNP | Other | Phase PHASE1 | Nonalcoholic Fatty Liver Disease (NAFLD) | COMPLETED | NCT06024408 |
| Supportive care | Other | Approved | Familial Hypercholesterolemia | RECRUITING | NCT06439654 |
| High-dose aflibercept | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT04429503 |
| aflibercept | Other | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT04429503 |
| Linvoseltamab | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT06376526 |
| Dupilumab | Other | Phase PHASE2 | Keloid | COMPLETED | NCT05128383 |
| Apixiban | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT05618808 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT05618808 |
| REGN9933 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT05618808 |
| Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04423718 |
| Aflibercept High Dose VEGF Trap-Eye (BAY86-5321) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04423718 |
| Pozelimab | Other | Phase PHASE2 | CD55-deficient Protein-losing Enteropathy | COMPLETED | NCT04209634 |
| Fianlimab | Other | Phase PHASE2 | Bladder Cancer | RECRUITING | NCT06571708 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Cancer | RECRUITING | NCT06571708 |
| Cisplatin | Other | Phase PHASE2 | Bladder Cancer | RECRUITING | NCT06571708 |
| Gemcitabine | Other | Phase PHASE2 | Bladder Cancer | RECRUITING | NCT06571708 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1909 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1908 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| Cemiplimab | Other | Preclinical | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT07064330 |
| cemiplimab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05259709 |
| 89Zr˗DFO˗REGN5054 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05259709 |
| Matching Placebo | Other | Phase PHASE1 | Obesity | WITHDRAWN | NCT06970405 |
| Garetosmab | Other | Phase PHASE1 | Obesity | WITHDRAWN | NCT06970405 |
| Placebo | Other | Phase PHASE2 | Pruritis | RECRUITING | NCT06226610 |
| Dupilumab | Other | Phase PHASE2 | Pruritis | RECRUITING | NCT06226610 |
| Placebo | Other | Phase PHASE2 | Uncontrolled Hypertension | TERMINATED | NCT06833190 |
| REGN5381 | Other | Phase PHASE2 | Uncontrolled Hypertension | TERMINATED | NCT06833190 |
| Matching Placebo-Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Garetosmab | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Fluorescein | Other | Phase PHASE3 | Macular Edema Secondary to Retinal Vein Occlusion | COMPLETED | NCT05850520 |
| Sham | Other | Phase PHASE3 | Macular Edema Secondary to Retinal Vein Occlusion | COMPLETED | NCT05850520 |
| Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg | Other | Phase PHASE3 | Macular Edema Secondary to Retinal Vein Occlusion | COMPLETED | NCT05850520 |
| Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose | Other | Phase PHASE3 | Macular Edema Secondary to Retinal Vein Occlusion | COMPLETED | NCT05850520 |
| Pozelimab/Cemdisiran | Other | Phase EARLY_PHASE1 | Sporadic Inclusion Body Myositis (sIBM) | RECRUITING | NCT06479863 |
| REGN7075 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Platinum-based chemotherapy | Drug | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Cemiplimab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Cemiplimab-Rwlc | Other | Phase PHASE2 | Non-small Cell Lung Cancer Stage III | RECRUITING | NCT06449313 |
| Mibavademab | Other | Phase PHASE3 | Monogenic Obesity | RECRUITING | NCT07220772 |
| Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| FDC fianlimab+cemiplimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06932562 |
| Lenalidomide | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06932562 |
| Daratumumab | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06932562 |
| Linvoseltamab | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06932562 |
| Sarilumab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| REGN7075 | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Ubamatamab | Other | Phase PHASE2 | Advanced/Metastatic Non-Small Cell Lung Cancer | RECRUITING | NCT07154290 |
| Kevzara (Sarilumab) | Other | Phase PHASE1 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05704634 |
| Cemiplimab | Other | Phase PHASE1 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05704634 |
| Ziv-Aflibercept | Other | Phase PHASE2 | Uveal Melanoma | TERMINATED | NCT03712904 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE2 | Uveal Melanoma | TERMINATED | NCT03712904 |
| cemiplimab+fianlimab | Other | Phase PHASE2 | Melanoma BRAF V600E/K Mutated | RECRUITING | NCT06887088 |
| Encorafenib + Binimetinib | Other | Phase PHASE2 | Melanoma BRAF V600E/K Mutated | RECRUITING | NCT06887088 |
| aflibercept 2mg | Other | Preclinical | Retinal Vasculitis | COMPLETED | NCT07105228 |
| Laser photocoagulation | Other | Phase PHASE3 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT04015180 |
| Eylea (Aflibercept, BAY86-5321) | Other | Phase PHASE3 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT04015180 |
| Odronextamab multiple dose levels | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT02290951 |
| Casirivimab+Imdevimab | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05181683 |
| casirivimab+imdevimab | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT05092581 |
| Aflibercept 8 mg | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06491914 |
| Odronextamab | Other | Phase PHASE2 | B-cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | NCT03888105 |
| cemiplimab | Other | Preclinical | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT03836105 |
| Matching Placebo | Other | Phase PHASE2 | Familial Partial Lipodystrophy | TERMINATED | NCT05088460 |
| REGN4461 | Other | Phase PHASE2 | Familial Partial Lipodystrophy | TERMINATED | NCT05088460 |
| Cemdisiran | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | NO_LONGER_AVAILABLE | NCT06028594 |
| Pozelimab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | NO_LONGER_AVAILABLE | NCT06028594 |
| Placebo | Other | Phase PHASE3 | Immunocompromised | TERMINATED | NCT05074433 |
| casirivimab+imdevimab | Other | Phase PHASE3 | Immunocompromised | TERMINATED | NCT05074433 |
| casirivimab+imdevimab | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04992273 |
| Moderna mRNA-1273 vaccine | Other | Phase PHASE2 | Healthy | COMPLETED | NCT04852978 |
| casirivimab+imdevimab | Other | Phase PHASE2 | Healthy | COMPLETED | NCT04852978 |
| bbT369 | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma (DLBCL) | TERMINATED | NCT05169489 |
| Cemiplimab | Other | Phase PHASE2 | Colon Cancer | RECRUITING | NCT05961709 |
| REGN7257 | Other | Phase PHASE1 | Severe Aplastic Anemia (SAA) | TERMINATED | NCT04409080 |
| Health Surveys | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | Other | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Evinacumab | Other | Preclinical | Pediatric Homozygous Familial Hypercholesterolemia (HoFH) | APPROVED_FOR_MARKETING | NCT06500598 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| casirivimab + imdevimab | Other | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| imdevimab | Other | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| REGN14256 | Other | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| aflibercept 2 mg | Other | Preclinical | Retinal Vasculitis | COMPLETED | NCT06769412 |
| Aflibercept (BAY86-5321, Eylea) | Other | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT06591598 |
| Cemiplimab | Other | Phase PHASE1 | Advanced NSCLC | TERMINATED | NCT04982224 |
| REGN5093-M114 | Other | Phase PHASE1 | Advanced NSCLC | TERMINATED | NCT04982224 |
| placebo | Other | Phase PHASE2 | Chronic Sinusitis | COMPLETED | NCT04362501 |
| dupilumab | Other | Phase PHASE2 | Chronic Sinusitis | COMPLETED | NCT04362501 |
| Placebo (blinded) | Other | Phase PHASE2 | Eosinophilic Gastritis | COMPLETED | NCT03678545 |
| Dupilumab (blinded) | Other | Phase PHASE2 | Eosinophilic Gastritis | COMPLETED | NCT03678545 |
| XL092 | Other | Phase PHASE1 | Anaplastic Thyroid Cancer | RECRUITING | NCT06902376 |
| Cemiplimab | Other | Phase PHASE1 | Anaplastic Thyroid Cancer | RECRUITING | NCT06902376 |
| Dupilumab | Other | Phase PHASE4 | Atopic Dermatitis | RECRUITING | NCT05268107 |
| Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | RECRUITING | NCT03972657 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | RECRUITING | NCT03972657 |
| Pozelimab | Other | Preclinical | CD55-Deficient Protein-Losing Enteropathy | APPROVED_FOR_MARKETING | NCT06003881 |
| Pozelimab | Other | Preclinical | CD55-deficient Protein-losing Enteropathy | APPROVED_FOR_MARKETING | NCT05232110 |
| REGN5458 | Other | Preclinical | Multiple Myeloma | APPROVED_FOR_MARKETING | NCT05164250 |
| dupilumab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| linvoseltamab | Other | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| Placebo | Other | Phase PHASE2 | Age-Related Macular Degeneration | COMPLETED | NCT02462889 |
| Intravitreal aflibercept injection | Other | Phase PHASE2 | Age-Related Macular Degeneration | COMPLETED | NCT02462889 |
| High-dose REGN4461 | Other | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Low-Dose REGN4461 | Other | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Placebo | Other | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Cemiplimab | Other | Preclinical | Non-Small Cell Lung Cancer (NSCLC) | APPROVED_FOR_MARKETING | NCT06132191 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT04590326 |
| Sarilumab | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT04590326 |
| Ubamatamab | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT04590326 |
| Cemiplimab | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT04590326 |
| REGN5668 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT04590326 |
| Dupilumab 300Mg Solution for Injection | Other | Phase PHASE2 | Pruritus | COMPLETED | NCT04256759 |
| Non-interventional | Other | Preclinical | Long Term Safety Following GM T Cell Therapy | RECRUITING | NCT06798298 |
| REGN3470-3471-3479 | Other | Preclinical | Ebola Virus Disease | AVAILABLE | NCT03576690 |
| Relatlimab + Nivolumab | Other | Preclinical | Locally Advanced Melanoma | RECRUITING | NCT07223411 |
| Fianlimab + Cemiplimab | Other | Preclinical | Locally Advanced Melanoma | RECRUITING | NCT07223411 |
| Topical imiquimod | Other | Phase PHASE1 | Cutaneous Basal Cell Carcinoma | RECRUITING | NCT07251413 |
| cemiplimab | Other | Phase PHASE1 | Cutaneous Basal Cell Carcinoma | RECRUITING | NCT07251413 |
| Tocilizumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cemiplimab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Ubamatamab | Other | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Cetuximab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Cemiplimab | Other | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| cemiplimab | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT04916002 |
| vidutolimod | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT04916002 |
| Odronextamab | Other | Preclinical | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | AVAILABLE | NCT05619367 |
| SC-DARIC33 | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05105152 |
| Garetosmab | Other | Preclinical | Fibrodysplasia Ossificans Progressiva (FOP) | TEMPORARILY_NOT_AVAILABLE | NCT07301450 |
| Sub-tenon injection of hyaluronidase (HA) alone | Other | Phase PHASE2 | Thyroid Eye Disease | COMPLETED | NCT04311606 |
| Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept | Other | Phase PHASE2 | Thyroid Eye Disease | COMPLETED | NCT04311606 |
| Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept | Other | Phase PHASE2 | Thyroid Eye Disease | COMPLETED | NCT04311606 |
| Rivaroxaban | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | NOT_YET_RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | NOT_YET_RECRUITING | NCT07318610 |
| REGN9933 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | NOT_YET_RECRUITING | NCT07318610 |
| REGN7508 | Other | Phase PHASE3 | Peripheral Artery Disease (PAD) | NOT_YET_RECRUITING | NCT07318610 |
| Placebo | Other | Phase PHASE2 | Allergies Food Milk | TERMINATED | NCT04148352 |
| Dupilumab | Other | Phase PHASE2 | Allergies Food Milk | TERMINATED | NCT04148352 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT06910124 |
| Linvoseltamab | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT06910124 |
| Cemiplimab | Other | Phase PHASE2 | SMARCB1-Deficient Malignancies | RECRUITING | NCT06444880 |
| Ubamatamab | Other | Phase PHASE2 | SMARCB1-Deficient Malignancies | RECRUITING | NCT06444880 |
| Vidutolimod | Other | Preclinical | Refractory Melanoma | NO_LONGER_AVAILABLE | NCT06063746 |
| Fianlimab+cemiplimab | Other | Phase PHASE2 | Melanoma | ENROLLING_BY_INVITATION | NCT06848088 |
| Placebo | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Cisplatin | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Carboplatin | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Paclitaxel | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Pemetrexed | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Cemiplimab | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Fianlimab | Other | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Dupilumab | Other | Phase PHASE4 | Dermal Hypersensitivity Reaction | COMPLETED | NCT06012448 |
| Placebo | Other | Phase PHASE2 | Heart Failure | TERMINATED | NCT06237309 |
| REGN5381 | Other | Phase PHASE2 | Heart Failure | TERMINATED | NCT06237309 |
| Placebo | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva | ACTIVE_NOT_RECRUITING | NCT05394116 |
| Garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva | ACTIVE_NOT_RECRUITING | NCT05394116 |
| Placebo | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT05347771 |
| Dupilumab | Other | Phase PHASE2 | Asthma | ACTIVE_NOT_RECRUITING | NCT05347771 |
| Cemiplimab | Other | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT03889912 |
| Placebo | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| Cisplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| Carboplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| Paclitaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| Pemetrexed | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| cemiplimab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| fianlimab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05800015 |
| Placebo | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05785767 |
| cemiplimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05785767 |
| fianlimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05785767 |
| Dupilumab | Other | Preclinical | Chronic Rhinosinusitis With Nasal Polyps | RECRUITING | NCT05246267 |
| Cevostamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Nirogacestat | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Cemiplimab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Fianlimab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Isatuximab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Ramucirumab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Docetaxel | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Cemiplimab | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| odronextamab | Other | Phase PHASE1 | Relapsed/Refractory Aggressive B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02651662 |
| cemiplimab | Other | Phase PHASE1 | Relapsed/Refractory Aggressive B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02651662 |
| Bevacizumab | Other | Phase PHASE1 | Epithelial Ovarian Cancer | RECRUITING | NCT06469281 |
| Cemiplimab | Other | Phase PHASE1 | Epithelial Ovarian Cancer | RECRUITING | NCT06469281 |
| 27T51 | Other | Phase PHASE1 | Epithelial Ovarian Cancer | RECRUITING | NCT06469281 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | RECRUITING | NCT05519475 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Other | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| Prednisone/Prednisolone | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Odronextamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06665828 |
| REGN9533 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06665828 |
| Prednisone/Prenisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| Placebo | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | RECRUITING | NCT06593600 |
| REGN7544 | Other | Phase PHASE2 | Postural Orthostatic Tachycardia Syndrome (POTS) | RECRUITING | NCT06593600 |
| Placebo | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06190951 |
| Fixed Dose Combination (FDC) cemiplimab+fianlimab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06190951 |
| cemiplimab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06190951 |
| Carboplatin (AUC 5) | Other | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Cisplatin | Other | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Pemetrexed (Alimta) | Other | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Fianlimab | Other | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Cemiplimab | Other | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Pozelimab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Cemdisiran | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Pozelimab + Cemdisiran | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Fianlimab | Other | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| Pemetrexed | Other | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| Platinum-doublet chemotherapy | Drug | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| Ipilimumab | Other | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| Cemiplimab | Other | Phase PHASE1 | Advanced Malignancies | ACTIVE_NOT_RECRUITING | NCT03233139 |
| REGN7544 | Other | Phase PHASE2 | Sepsis-Induced Hypotension | ACTIVE_NOT_RECRUITING | NCT06608901 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| relatlimab+nivolumab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| cemiplimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| fianlimab | Other | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Placebo (PB) | Other | Phase PHASE1 | Healthy Volunteers With Hyperlipidemia | ACTIVE_NOT_RECRUITING | NCT06452771 |
| ALN-ANG3 | Other | Phase PHASE1 | Healthy Volunteers With Hyperlipidemia | ACTIVE_NOT_RECRUITING | NCT06452771 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06669234 |
| ALN-F1202 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06669234 |
| DB-OTO | Other | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| Rimiducid | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT02744287 |
| BPX-601 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT02744287 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05133531 |
| Placebo (PB) | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| Diluent | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| ALN-SOD | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| Sarilumab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN5678 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Cemiplimab | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| REGN4336 | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Dupilumab | Other | Phase PHASE4 | Allergic Contact Dermatitis | ACTIVE_NOT_RECRUITING | NCT03935971 |
| Fianlimab 1600 MG Intravenous Solution | Other | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07223541 |
| Cemiplimab 350 MG Intravenous Solution | Other | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07223541 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06454630 |
| Cemiplimab | Other | Phase PHASE2 | HPV-Related Squamous Cell Carcinoma | RECRUITING | NCT04988074 |
| Cemiplimab | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5678 | Other | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| Chemotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | SUSPENDED | NCT06385262 |
| Cemiplimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | SUSPENDED | NCT06385262 |
| Alirocumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | SUSPENDED | NCT06385262 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT05730036 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT05730036 |
| Elotuzumab | Other | Phase PHASE3 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT05730036 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT05730036 |
| Placebo | Other | Phase PHASE2 | Asthma, Allergic | RECRUITING | NCT05720325 |
| House Dust Mites (HDM) | Other | Phase PHASE2 | Asthma, Allergic | RECRUITING | NCT05720325 |
| Dupilumab | Other | Phase PHASE2 | Asthma, Allergic | RECRUITING | NCT05720325 |
| Cemiplimab | Other | Phase PHASE2 | Basal Cell Carcinoma (BCC) | RECRUITING | NCT06981325 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Odronextamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| REGN4461 | Other | Preclinical | Lipodystrophy | AVAILABLE | NCT04710056 |
| Odronextamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT07128641 |
| Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Questionnaire Administration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Lumbar Puncture | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Computed Tomography | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | Drug | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Biospecimen Collection | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Odronextamab | Other | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Daratumumab | Other | Phase PHASE3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | NOT_YET_RECRUITING | NCT07393282 |
| Linvoseltamab | Other | Phase PHASE3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | NOT_YET_RECRUITING | NCT07393282 |
| Matching Placebo | Other | Phase PHASE1 | Dyslipidemia | COMPLETED | NCT06784349 |
| ALN-APOC3 | Other | Phase PHASE1 | Dyslipidemia | COMPLETED | NCT06784349 |
| Alirocumab | Other | Phase PHASE2 | Hypercholesterolemia | NOT_YET_RECRUITING | NCT07477704 |
| Placebo | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| ALN-CFB | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT06205836 |
| Placebo | Other | Phase PHASE2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | RECRUITING | NCT06421636 |
| REGN7999 | Other | Phase PHASE2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | RECRUITING | NCT06421636 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05744921 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05744921 |
| REGN5093 | Other | Phase PHASE1 | NSCLC | RECRUITING | NCT04077099 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05828511 |
| Non-Interventional | Other | Preclinical | Hemophilia B | ACTIVE_NOT_RECRUITING | NCT05568459 |
| Fianlimab | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Biopsy | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Biospecimen Collection | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Computed Tomography | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Cemiplimab | Other | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | NOT_YET_RECRUITING | NCT07493304 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | NOT_YET_RECRUITING | NCT07493304 |
| Biospecimen Collection | Other | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Positron Emission Tomography | Other | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Computed Tomography | Other | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Bone Marrow Biopsy | Other | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Bone Marrow Aspiration | Other | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Linvoseltamab | Other | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Placebo | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | RECRUITING | NCT06128629 |
| NTLA-2001 | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | RECRUITING | NCT06128629 |
| Non-Interventional | Other | Preclinical | Retinopathy of Prematurity | ACTIVE_NOT_RECRUITING | NCT04515524 |
| Placebo | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03969004 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03969004 |
| REGN5837 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Odronextamab | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Paclitaxel | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Post-operative radiation therapy | Drug | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Surgical Resection of Primary +/- Neck Dissection | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Cemiplimab | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Cetuximab | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Docetaxel | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Carboplatin | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Cisplatin | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| ubamatamab | Other | Preclinical | Renal Medullary Carcinoma (RMC) | AVAILABLE | NCT07502716 |
| Sham | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT06422507 |
| 2 mg aflibercept (EYLEA, BAY 86-5321) | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT06422507 |
| 8 mg aflibercept (BAY 86-5321) (High Dose) | Other | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT06422507 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Capecitabine | Other | Phase PHASE1 | Hormone Receptor-positive Breast Cancer | COMPLETED | NCT05064085 |
| Cemiplimab | Other | Phase PHASE1 | Hormone Receptor-positive Breast Cancer | COMPLETED | NCT05064085 |
| fianlimab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03916627 |
| Platinum Doublet | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03916627 |
| cemiplimab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03916627 |
| mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | ACTIVE_NOT_RECRUITING | NCT06548100 |
| Sarilumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| PLD | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Fianlimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Cemiplimab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Gemcitabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Cytarabine | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Cisplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Dexamethasone | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Rituximab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Etoposide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Carboplatin | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Ifosfamide | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Odronextamab | Other | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Linvoseltamab | Other | Phase PHASE2 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | RECRUITING | NCT06140524 |
| Placebo | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| REGN7508 | Other | Phase PHASE3 | Cancer-Associated Thrombosis (CAT) | RECRUITING | NCT07410117 |
| Placebo | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Enoxaparin | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Apixaban | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 | Other | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| Cemiplimab Plus Gemcitabine | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (mPDAC) | RECRUITING | NCT06790602 |
| Placebo | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Cemdisiran | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Pozelimab | Other | Phase PHASE3 | Age-related Macular Degeneration (AMD) | RECRUITING | NCT06541704 |
| Trifluridine-tipiracil | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| Bevacizumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| Platinum-based doublet chemotherapy | Drug | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| Cemiplimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| REGN7075 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| Placebo | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Mibavademab | Other | Phase PHASE3 | Generalized Lipodystrophy | RECRUITING | NCT07220785 |
| Pozelimab | Other | Phase PHASE4 | CHAPLE Disease | RECRUITING | NCT07142343 |
| Odronextamab | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| Vonsetamig | Other | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| Platinum Doublet Chemotherapy (PDC) | Drug | Phase PHASE2 | NSCLC | RECRUITING | NCT06865339 |
| Radiotherapy | Drug | Phase PHASE2 | NSCLC | RECRUITING | NCT06865339 |
| Fianlimab | Other | Phase PHASE2 | NSCLC | RECRUITING | NCT06865339 |
| Cemiplimab | Other | Phase PHASE2 | NSCLC | RECRUITING | NCT06865339 |
| REGN7945+Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT06669247 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT06669247 |
| Placebo | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06299111 |
| REGN7508 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06299111 |
| REGN9933 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT06299111 |
| Rituximab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Odronextamab | Other | Phase PHASE3 | Relapsed/Refractory Follicular Lymphoma | RECRUITING | NCT06149286 |
| Linvoseltamab | Other | Phase PHASE2 | Smoldering Multiple Myeloma (SMM) | ACTIVE_NOT_RECRUITING | NCT05955508 |
| Alirocumab and Cemiplimab | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05553834 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | NOT_YET_RECRUITING | NCT07527910 |
| Tirzepatide | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | NOT_YET_RECRUITING | NCT07527910 |
| ALN-PNP | Other | Phase PHASE2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | NOT_YET_RECRUITING | NCT07527910 |
| Placebo | Other | Phase PHASE1 | Parkinsons Disease | RECRUITING | NCT07216066 |
| ALN-SNCA | Other | Phase PHASE1 | Parkinsons Disease | RECRUITING | NCT07216066 |
| Cemiplimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT06931717 |
| REGN17372+Linvoseltamab | Other | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07455851 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07455851 |
| LNP1265 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | Other | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| Normal Saline as Placebo | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| nexiguran ziclumeran | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| Placebo (PB) | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| ALN-PNP | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| Noninterventional | Other | Preclinical | Chronic Kidney Disease (CKD) | RECRUITING | NCT05106387 |
| Linvoseltamab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT03761108 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva (FOP) | NOT_YET_RECRUITING | NCT07559513 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva (FOP) | NOT_YET_RECRUITING | NCT07559513 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Fianlimab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Radical cystectomy | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab | Other | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva (FOP) | NOT_YET_RECRUITING | NCT07559513 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva (FOP) | NOT_YET_RECRUITING | NCT07559513 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva (FOP) | NOT_YET_RECRUITING | NCT07559513 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| ALN-HSD | Other | Phase PHASE2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | RECRUITING | NCT05519475 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05133531 |
| garetosmab | Other | Phase PHASE3 | Fibrodysplasia Ossificans Progressiva (FOP) | NOT_YET_RECRUITING | NCT07559513 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Linvoseltamab | Other | Phase PHASE1 | Relapsed/Refractory Systemic Light Chain Amyloidosis | RECRUITING | NCT06292780 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Placebo | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Mibavademab | Other | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| Placebo | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Olatorepatide | Other | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| REGN7075 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Fianlimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Cemiplimab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Capecitabine | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Oxaliplatin | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN9933 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| REGN7508 | Other | Phase PHASE3 | Atrial Fibrillation (AF) | RECRUITING | NCT07430956 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Cemiplimab | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| REGN10597 | Other | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| Aspirin Challenge | Other | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | COMPLETED | NCT05031455 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Grazax® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | Other | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Vonsetamig | Other | Phase PHASE1 | Chronic Kidney Disease (CKD) | RECRUITING | NCT05092347 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Placebo | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Acetylsalicylic Acid (ASA) | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| REGN7508 | Other | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Cemdisiran | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Pozelimab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Apixaban | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN9933 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| REGN7508 | Other | Phase PHASE2 | Atrial Fibrillation (AF) | RECRUITING | NCT07175428 |
| Health surveys | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Saliva sample | Other | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pozelimab | Other | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Bortezomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Pomalidomide | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Carfilzomib | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Linvoseltamab | Other | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Ipilimumab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Cemiplimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| Fianlimab | Other | Phase PHASE2 | Advanced Melanoma | RECRUITING | NCT06594991 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| Standard of care | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Cemiplimab | Other | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Platinum-based chemotherapy | Drug | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| Cemiplimab | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05363319 |
| REGN7041 | Other | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | ACTIVE_NOT_RECRUITING | NCT07218770 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Cemiplimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Fianlimab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05352672 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5715 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| REGN5713 | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602739 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| REGN13335 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | RECRUITING | NCT07318597 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| BPX-601 | Other | Phase PHASE1 | Prostate Cancer | NOT_YET_RECRUITING | NCT07543055 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | Drug | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Cemiplimab | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. | Other | Phase PHASE2 | Merkel Cell Carcinoma, Stage I | NOT_YET_RECRUITING | NCT07387198 |
| Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles | Other | Phase PHASE2 | Merkel Cell Carcinoma, Stage I | NOT_YET_RECRUITING | NCT07387198 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Placebo (PB) | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| ALN-PNP | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| Noninterventional | Other | Preclinical | Chronic Kidney Disease (CKD) | RECRUITING | NCT05106387 |
| Normal Saline as Placebo | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| nexiguran ziclumeran | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Placebo (PB) | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| ALN-PNP | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| Normal Saline as Placebo | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| nexiguran ziclumeran | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Placebo | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| ALN-CIDEB | Other | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Placebo (PB) | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| ALN-PNP | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT05648214 |
| Normal Saline as Placebo | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| nexiguran ziclumeran | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Normal Saline as Placebo | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| nexiguran ziclumeran | Other | Phase PHASE3 | Neuromuscular Disease | RECRUITING | NCT06672237 |
| Evinacumab placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Evinacumab | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 | Other | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Microcrystalline cellulose | DRUG | Phase PHASE1 | Lewy Body Disease | UNKNOWN | NCT04963855 |
| GT300 | DRUG | Phase PHASE1 | Lewy Body Disease | UNKNOWN | NCT04963855 |
| ubamatamab | DRUG | Preclinical | Renal Medullary Carcinoma (RMC) | AVAILABLE | NCT07502716 |
| REGN17372+Linvoseltamab | DRUG | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07455851 |
| Adjuvant chemotherapy | DRUG | Phase PHASE2 | Lung Cancer (NSCLC) | NOT_YET_RECRUITING | NCT07450183 |
| Olatorepatide | DRUG | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| Radical cystectomy | PROCEDURE | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Cemiplimab and Fianlimab | DRUG | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Stereotactic body radiotherapy | RADIATION | Phase PHASE2 | Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07414992 |
| Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. | DRUG | Phase PHASE2 | Merkel Cell Carcinoma, Stage I | NOT_YET_RECRUITING | NCT07387198 |
| Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles | DRUG | Phase PHASE2 | Merkel Cell Carcinoma, Stage I | NOT_YET_RECRUITING | NCT07387198 |
| Arm 2 cemiplimab and fianlimab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07365839 |
| Arm 1 cemiplimab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07365839 |
| Oxaliplatin | DRUG | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| Evinacumab placebo | DRUG | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| ALN-ANG3 placebo | DRUG | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Topical imiquimod | DRUG | Phase PHASE1 | Cutaneous Basal Cell Carcinoma | RECRUITING | NCT07251413 |
| Carboplatin (AUC 5) | DRUG | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Pemetrexed (Alimta) | DRUG | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Fianlimab 1600 MG Intravenous Solution | DRUG | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07223541 |
| Cemiplimab 350 MG Intravenous Solution | DRUG | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07223541 |
| Relatlimab + Nivolumab | DRUG | Preclinical | Locally Advanced Melanoma | RECRUITING | NCT07223411 |
| Fianlimab + Cemiplimab | DRUG | Preclinical | Locally Advanced Melanoma | RECRUITING | NCT07223411 |
| Mibavademab | DRUG | Phase PHASE2 | Functional Hypothalamic Amenorrhea (FHA) | RECRUITING | NCT07235917 |
| REGN7041 | DRUG | Phase PHASE1 | Active Noninfectious Uveitis Affecting the Posterior Segment | RECRUITING | NCT07218770 |
| Health surveys | OTHER | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| ALN-SNCA | DRUG | Phase PHASE1 | Parkinsons Disease | RECRUITING | NCT07216066 |
| Acetylsalicylic Acid (ASA) | DRUG | Phase PHASE3 | Symptomatic Venous Thromboembolism (VTE) | RECRUITING | NCT07213778 |
| Nivolumab | DRUG | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| ALN-CFB | DRUG | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | RECRUITING | NCT07187401 |
| aflibercept 2mg | DRUG | Preclinical | Retinal Vasculitis | COMPLETED | NCT07105228 |
| ctDNA testing | OTHER | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| cemiplimab + REGN7075 | DRUG | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| cemiplimab plus fianlimab | DRUG | Phase PHASE2 | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07058012 |
| Apixaban | DRUG | Phase PHASE3 | Venous Thromboembolism (VTE) | NOT_YET_RECRUITING | NCT07493304 |
| XL092 | DRUG | Phase PHASE1 | Anaplastic Thyroid Cancer | RECRUITING | NCT06902376 |
| cemiplimab+fianlimab | DRUG | Phase PHASE2 | Melanoma BRAF V600E/K Mutated | RECRUITING | NCT06887088 |
| Encorafenib + Binimetinib | DRUG | Phase PHASE2 | Melanoma BRAF V600E/K Mutated | RECRUITING | NCT06887088 |
| Platinum Doublet Chemotherapy (PDC) | DRUG | Phase PHASE2 | NSCLC | RECRUITING | NCT06865339 |
| Radiotherapy | RADIATION | Phase PHASE2 | NSCLC | RECRUITING | NCT06865339 |
| Fianlimab+cemiplimab | DRUG | Phase PHASE2 | Melanoma | ENROLLING_BY_INVITATION | NCT06848088 |
| ALN-CIDEB | DRUG | Phase PHASE1 | Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT06836609 |
| Non-interventional | GENETIC | Preclinical | Long Term Safety Following GM T Cell Therapy | RECRUITING | NCT06798298 |
| Cemiplimab Plus Gemcitabine | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (mPDAC) | RECRUITING | NCT06790602 |
| PLD | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Positron Emission Tomography | PROCEDURE | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Lumbar Puncture | PROCEDURE | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Leukapheresis | PROCEDURE | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Chimeric Antigen Receptor T-Cell Therapy | BIOLOGICAL | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Bone Marrow Biopsy | PROCEDURE | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Bone Marrow Aspiration | PROCEDURE | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| ALN-APOC3 | DRUG | Phase PHASE1 | Dyslipidemia | COMPLETED | NCT06784349 |
| Health Surveys | OTHER | Preclinical | Breast Cancer Risk | RECRUITING | NCT06773897 |
| Saliva sample | GENETIC | Preclinical | Kidney Disease | RECRUITING | NCT07217535 |
| FDC fianlimab+cemiplimab | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT06769698 |
| aflibercept 2 mg | DRUG | Preclinical | Retinal Vasculitis | COMPLETED | NCT06769412 |
| Normal Saline as Placebo | DRUG | Phase PHASE3 | Neuromuscular Disease | ACTIVE_NOT_RECRUITING | NCT06672237 |
| nexiguran ziclumeran | BIOLOGICAL | Phase PHASE3 | Neuromuscular Disease | ACTIVE_NOT_RECRUITING | NCT06672237 |
| REGN7945+Linvoseltamab | DRUG | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT06669247 |
| ALN-F1202 | DRUG | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06669234 |
| Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] | DRUG | Phase PHASE4 | Eosinophilic Esophagitis (EoE) | RECRUITING | NCT06665971 |
| REGN9533 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06665828 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | DRUG | Phase PHASE4 | Diabetic Macular Edema (DME) | RECRUITING | NCT06662994 |
| Stereotactic body radiation therapy | RADIATION | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Platinum based chemotherapy | DRUG | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623656 |
| Ramucirumab | BIOLOGICAL | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| PB | DRUG | Phase PHASE2 | Sepsis-Induced Hypotension | ACTIVE_NOT_RECRUITING | NCT06608901 |
| REGN1909 | DRUG | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| REGN1908 | DRUG | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT06602726 |
| Aflibercept (BAY86-5321, Eylea) | DRUG | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT06591598 |
| Standard of care | PROCEDURE | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| mibavademab | DRUG | Phase PHASE3 | Generalized Lipodystrophy | ACTIVE_NOT_RECRUITING | NCT06548100 |
| Aflibercept 8 mg | DRUG | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06491914 |
| 27T51 | OTHER | Phase PHASE1 | Epithelial Ovarian Cancer | RECRUITING | NCT06469281 |
| ALN-ANG3 | DRUG | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| Rivaroxaban | DRUG | Phase PHASE3 | Peripheral Artery Disease (PAD) | NOT_YET_RECRUITING | NCT07318610 |
| Supportive care | OTHER | Approved | Familial Hypercholesterolemia | RECRUITING | NCT06439654 |
| 2 mg aflibercept (EYLEA, BAY 86-5321) | DRUG | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT06422507 |
| 8 mg aflibercept (BAY 86-5321) (High Dose) | DRUG | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT06422507 |
| REGN10597 | DRUG | Phase PHASE1 | Melanoma | RECRUITING | NCT06413680 |
| aflibercept 8 mg | DRUG | Preclinical | Neovascular Age-related Macular Degeneration (nAMD) | WITHDRAWN | NCT06398080 |
| Chemotherapy | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | SUSPENDED | NCT06385262 |
| LNP1265 | DRUG | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| REGV131 | DRUG | Phase PHASE1 | Hemophilia B | RECRUITING | NCT06379789 |
| linvoseltamab | DRUG | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| Diluent | OTHER | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| ALN-SOD | DRUG | Phase PHASE1 | Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | NCT06351592 |
| REGN7508 | DRUG | Phase PHASE3 | Venous Thromboembolism (VTE) | NOT_YET_RECRUITING | NCT07493304 |
| Matching Placebo-Garetosmab | DRUG | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Trevogrumab | DRUG | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Matching Placebo-Part A | DRUG | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Semaglutide | DRUG | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part B and Part C | DRUG | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| Trevogrumab-Part A | DRUG | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06299098 |
| relatlimab+nivolumab | DRUG | Phase PHASE3 | Melanoma | RECRUITING | NCT06246916 |
| Cytarabine | DRUG | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Fixed Dose Combination (FDC) cemiplimab+fianlimab | DRUG | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT06190951 |
| S095029 RDE | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06162572 |
| S095024 RDE | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06162572 |
| S095018 Recommended Dose Expansion (RDE) | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06162572 |
| S095029 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06162572 |
| S095024 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06162572 |
| S095018 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT06162572 |
| REGN13335 | DRUG | Phase PHASE2 | Pulmonary Arterial Hypertension (PAH) | NOT_YET_RECRUITING | NCT07318597 |
| Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation | PROCEDURE | Preclinical | Chronic Rhinosinusitis With Nasal Polyps | RECRUITING | NCT06129552 |
| NTLA-2001 | BIOLOGICAL | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | RECRUITING | NCT06128629 |
| Hyperpolarized Xe129 | DRUG | Phase PHASE2 | Pulmonary Artery Hypertension | WITHDRAWN | NCT06122922 |
| Prednisone/Prenisolone | DRUG | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Prednisone/Prednisolone | DRUG | Phase PHASE3 | Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | NCT06091865 |
| Bendamustine | DRUG | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Prednisone/prednisolone | DRUG | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06091254 |
| Vincristine | DRUG | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Doxorubicin | DRUG | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Cyclophosphamide | DRUG | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06097364 |
| Vidutolimod | DRUG | Preclinical | Refractory Melanoma | NO_LONGER_AVAILABLE | NCT06063746 |
| CAR T-cells (TBC) | BIOLOGICAL | Phase PHASE2 | B-cell Non Hodgkin Lymphoma | RECRUITING | NCT05991388 |
| Etoposide Phosphate | DRUG | Phase PHASE2 | B-cell Non Hodgkin Lymphoma | RECRUITING | NCT05991388 |
| Etoposide | DRUG | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Ifosfamide | DRUG | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Rituximab | DRUG | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Loncastuximab tesirine | DRUG | Phase PHASE2 | B-cell Non Hodgkin Lymphoma | RECRUITING | NCT05991388 |
| aflibercept 8 mg PFS | DRUG | Phase PHASE3 | Diabetic Macular Edema (DME) | COMPLETED | NCT05989126 |
| REGN7544 | DRUG | Phase PHASE2 | Sepsis-Induced Hypotension | ACTIVE_NOT_RECRUITING | NCT06608901 |
| Biopsy | PROCEDURE | Phase PHASE2 | Recurrent Diffuse Large B-Cell Lymphoma | RECRUITING | NCT06784726 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Quality-of-Life Assessment | OTHER | Phase PHASE2 | Locally Advanced Basal Cell Carcinoma | RECRUITING | NCT05929664 |
| Biospecimen Collection | PROCEDURE | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| Computed Tomography | PROCEDURE | Phase PHASE1 | Recurrent Multiple Myeloma | RECRUITING | NCT07181941 |
| REGN17092 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05923424 |
| Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg | DRUG | Phase PHASE3 | Macular Edema Secondary to Retinal Vein Occlusion | COMPLETED | NCT05850520 |
| Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose | DRUG | Phase PHASE3 | Macular Edema Secondary to Retinal Vein Occlusion | COMPLETED | NCT05850520 |
| Non Applicable | OTHER | Preclinical | Intraocular Inflammation | COMPLETED | NCT05791695 |
| DB-OTO | GENETIC | Phase PHASE1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | RECRUITING | NCT05788536 |
| Dexamethasone | DRUG | Phase PHASE2 | Multiple Myeloma (MM) | NOT_YET_RECRUITING | NCT07428369 |
| Elotuzumab | DRUG | Phase PHASE3 | Relapsed Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT05730036 |
| PEG-IFN alfa-2a | DRUG | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT05729139 |
| House Dust Mites (HDM) | OTHER | Phase PHASE2 | Asthma, Allergic | RECRUITING | NCT05720325 |
| Kevzara (Sarilumab) | DRUG | Phase PHASE1 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05704634 |
| REGN5837 | DRUG | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | RECRUITING | NCT05685173 |
| Placebo (PB) | DRUG | Phase PHASE1 | Healthy Volunteers With Hyperlipidemia | ACTIVE_NOT_RECRUITING | NCT06452771 |
| ALN-PNP | DRUG | Phase PHASE1 | Nonalcoholic Fatty Liver Disease (NAFLD) | COMPLETED | NCT06024408 |
| Apixiban | DRUG | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT05618808 |
| Enoxaparin | DRUG | Phase PHASE3 | Venous Thromboembolism (VTE) | RECRUITING | NCT07015905 |
| REGN7508 (SC) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| REGN7508 (IV) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| rivaroxaban high dose | DRUG | Approved | Healthy Volunteer | COMPLETED | NCT05546957 |
| rivaroxaban low dose | DRUG | Approved | Healthy Volunteer | COMPLETED | NCT05546957 |
| Aspirin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06444178 |
| ALN-HSD | DRUG | Phase PHASE2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | RECRUITING | NCT05519475 |
| REGN14284 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05505448 |
| REGN7999 | DRUG | Phase PHASE2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | RECRUITING | NCT06421636 |
| No Intervention | PROCEDURE | Approved | Non-alcoholic Steatohepatitis (NASH) | TERMINATED | NCT05423327 |
| Garetosmab | DRUG | Preclinical | Fibrodysplasia Ossificans Progressiva (FOP) | TEMPORARILY_NOT_AVAILABLE | NCT07301450 |
| Platinum-based chemotherapy | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT06465329 |
| Matching Placebo (SC) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| REGN15160 (SC) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05293678 |
| Matching Placebo (IV) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05603195 |
| REGN15160 (IV) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05293678 |
| REGN9035 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05291546 |
| Dupixent | DRUG | Phase PHASE4 | Atopic Dermatitis | RECRUITING | NCT05285839 |
| Reflectance confocal microscopy | DEVICE | Phase PHASE4 | Eczema | UNKNOWN | NCT05265234 |
| Optical Coherence Tomography | DEVICE | Phase PHASE4 | Eczema | UNKNOWN | NCT05265234 |
| 89Zr˗DFO˗REGN5054 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05259709 |
| Inmazeb | DRUG | Phase PHASE2 | Ebola Virus Disease | NOT_YET_RECRUITING | NCT05202288 |
| Ervebo | BIOLOGICAL | Phase PHASE2 | Ebola Virus Disease | NOT_YET_RECRUITING | NCT05202288 |
| Casirivimab+Imdevimab | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05181683 |
| bbT369 | BIOLOGICAL | Phase PHASE1 | Diffuse Large B Cell Lymphoma (DLBCL) | TERMINATED | NCT05169489 |
| REGN5458 | DRUG | Preclinical | Multiple Myeloma | APPROVED_FOR_MARKETING | NCT05164250 |
| Casirivimab and Imdevimab Antibody Cocktail | DRUG | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT05157997 |
| Cevostamab | DRUG | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Nirogacestat | DRUG | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Isatuximab | DRUG | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT05137054 |
| Pomalidomide | DRUG | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Bortezomib | DRUG | Phase PHASE2 | Multiple Myeloma (MM) | NOT_YET_RECRUITING | NCT07428369 |
| Lenalidomide | DRUG | Phase PHASE2 | Multiple Myeloma (MM) | NOT_YET_RECRUITING | NCT07428369 |
| Carfilzomib | DRUG | Phase PHASE3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | RECRUITING | NCT07222761 |
| Daratumumab | DRUG | Phase PHASE2 | Multiple Myeloma (MM) | NOT_YET_RECRUITING | NCT07428369 |
| Ravulizumab | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05133531 |
| Eculizumab | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT05133531 |
| REGN4336 | DRUG | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05125016 |
| Noninterventional | DRUG | Preclinical | Chronic Kidney Disease (CKD) | RECRUITING | NCT05106387 |
| SC-DARIC33 | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05105152 |
| REGN9933 | DRUG | Phase PHASE3 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT07430956 |
| Dupilumab Prefilled Syringe | DRUG | Phase PHASE4 | Nasal Polyps | RECRUITING | NCT05094570 |
| Vonsetamig | DRUG | Phase PHASE1 | Lupus Nephritis (LN) | RECRUITING | NCT06975787 |
| casirivimab + imdevimab | DRUG | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| imdevimab | DRUG | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| REGN14256 | DRUG | Phase PHASE1 | SARS-CoV-2 | TERMINATED | NCT05081388 |
| Pozelimab + Cemdisiran | DRUG | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05070858 |
| Capecitabine | DRUG | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| IO-108 + cemiplimab combination therapy | BIOLOGICAL | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT05054348 |
| IO-108 + pembrolizumab combination therapy | BIOLOGICAL | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT05054348 |
| IO-108 | BIOLOGICAL | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT05054348 |
| Aspirin Challenge | DRUG | Phase PHASE2 | Aspirin-exacerbated Respiratory Disease | RECRUITING | NCT05031455 |
| Surveys | OTHER | Preclinical | Post-acute COVID-19 (PACS), or "long COVID" Syndrome | COMPLETED | NCT05013723 |
| REGN5093-M114 | DRUG | Phase PHASE1 | Advanced NSCLC | TERMINATED | NCT04982224 |
| vidutolimod | DRUG | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT04916002 |
| Moderna mRNA-1273 vaccine | BIOLOGICAL | Phase PHASE2 | Healthy | COMPLETED | NCT04852978 |
| casirivimab+imdevimab | DRUG | Phase PHASE1 | COVID-19 | TERMINATED | NCT05092581 |
| Post-operative radiation therapy | RADIATION | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Surgical Resection of Primary +/- Neck Dissection | PROCEDURE | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT04722523 |
| Carboplatin | DRUG | Phase PHASE3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | RECRUITING | NCT06230224 |
| Cisplatin | DRUG | Phase PHASE2 | Pleural Mesotheliomas | NOT_YET_RECRUITING | NCT07234058 |
| Kinetics test | OTHER | Approved | Hypercholesterolemia, Familial | COMPLETED | NCT04722068 |
| REGN5715 | DRUG | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| REGN5714 | DRUG | Phase PHASE2 | Allergic Rhinitis | COMPLETED | NCT05430919 |
| REGN5713 | DRUG | Phase PHASE3 | Allergic Conjunctivitis | RECRUITING | NCT07309432 |
| 89Zr-DFO-REGN3767 | OTHER | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04706715 |
| Trifluridine-tipiracil | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| Bevacizumab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Platinum-based doublet chemotherapy | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT04626635 |
| REGN7075 | DRUG | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07281768 |
| REGN6490 | DRUG | Phase PHASE1 | Healthy Volunteer | TERMINATED | NCT04616105 |
| Cemdisiran | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | RECRUITING | NCT07154745 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | DRUG | Phase PHASE2 | Colon Cancer | NOT_YET_RECRUITING | NCT07224022 |
| REGN5668 | DRUG | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT04590326 |
| garetosmab | DRUG | Phase PHASE3 | Fibrodyplasia Ossificans Progressiva (FOP) | WITHDRAWN | NCT04577820 |
| Nab paclitaxel | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT04543071 |
| Motixafortide | DRUG | Phase PHASE2 | Pancreatic Cancer | RECRUITING | NCT04543071 |
| Dupilumab Only Product | DRUG | Phase PHASE4 | Atopic Dermatitis | UNKNOWN | NCT04520308 |
| REGN10933+REGN10987 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04519437 |
| Non-Interventional | OTHER | Preclinical | Fibrodysplasia Ossificans Progressiva (FOP) | COMPLETED | NCT06064656 |
| REGN5381 | DRUG | Phase PHASE2 | Uncontrolled Hypertension | TERMINATED | NCT06833190 |
| Grazax® Placebo | DRUG | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® Placebo | DRUG | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Grazax® | BIOLOGICAL | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| Dupixent® | BIOLOGICAL | Phase PHASE2 | Allergic Rhinoconjunctivitis | COMPLETED | NCT04502966 |
| REGN6569 | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT04465487 |
| REGN10933 + REGN10987 | DRUG | Phase PHASE3 | Healthy Participants | COMPLETED | NCT04452318 |
| REGN10933+REGN10987 combination therapy | DRUG | Phase PHASE2 | COVID-19 | COMPLETED | NCT04666441 |
| casirivimab+imdevimab combination therapy | DRUG | Phase PHASE3 | COVID-19 | TERMINATED | NCT04425629 |
| Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321) | DRUG | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04423718 |
| Aflibercept High Dose VEGF Trap-Eye (BAY86-5321) | DRUG | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04423718 |
| REGN7257 | DRUG | Phase PHASE1 | Severe Aplastic Anemia (SAA) | TERMINATED | NCT04409080 |
| Dupilumab Injectable Product | DRUG | Phase PHASE4 | Asthma | RECRUITING | NCT04380038 |
| Prednisone | DRUG | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Sirolimus | DRUG | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Everolimus | DRUG | Phase PHASE1 | Cutaneous Squamous Cell Carcinoma | COMPLETED | NCT04339062 |
| Sub-tenon injection of hyaluronidase (HA) alone | DRUG | Phase PHASE2 | Thyroid Eye Disease | COMPLETED | NCT04311606 |
| Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept | DRUG | Phase PHASE2 | Thyroid Eye Disease | COMPLETED | NCT04311606 |
| Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept | DRUG | Phase PHASE2 | Thyroid Eye Disease | COMPLETED | NCT04311606 |
| VV1 | BIOLOGICAL | Phase PHASE2 | Melanoma | RECRUITING | NCT04291105 |
| Dupilumab 300Mg Solution for Injection | DRUG | Phase PHASE2 | Pruritus | COMPLETED | NCT04256759 |
| Cemiplimab-Rwlc | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer Stage III | RECRUITING | NCT06449313 |
| Pozelimab | DRUG | Phase PHASE1 | Geographic Atrophy (GA) | RECRUITING | NCT07230834 |
| dupilumab | DRUG | Phase PHASE1 | Food Allergy | RECRUITING | NCT06369467 |
| High-dose REGN4461 | DRUG | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| Low-Dose REGN4461 | DRUG | Phase PHASE2 | Generalized Lipodystrophy | COMPLETED | NCT04159415 |
| High-dose aflibercept | DRUG | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT04429503 |
| laser photocoagulation | PROCEDURE | Phase PHASE3 | Retinopathy of Prematurity | COMPLETED | NCT04101721 |
| REGN5459 | DRUG | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT04083534 |
| REGN5093 | DRUG | Phase PHASE1 | NSCLC | RECRUITING | NCT04077099 |
| RP1 | BIOLOGICAL | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04050436 |
| Laser photocoagulation | PROCEDURE | Phase PHASE3 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT04015180 |
| Eylea (Aflibercept, BAY86-5321) | DRUG | Phase PHASE3 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT04015180 |
| REGN5678 | DRUG | Phase PHASE1 | Prostate Cancer | RECRUITING | NCT06826768 |
| REGN5713-5714-5715 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03969849 |
| Matching Placebo | DRUG | Phase PHASE1 | Obesity | WITHDRAWN | NCT06970405 |
| Docetaxel | DRUG | Phase PHASE2 | Recurrent Lung Non-Small Cell Carcinoma | RECRUITING | NCT06616584 |
| Leuprolide Acetate | DRUG | Phase PHASE2 | Prostate Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT03951831 |
| Degarelix | DRUG | Phase PHASE2 | Prostate Cancer Metastatic | ACTIVE_NOT_RECRUITING | NCT03951831 |
| fianlimab | DRUG | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | WITHDRAWN | NCT06384820 |
| Platinum Doublet | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03916627 |
| Odronextamab | BIOLOGICAL | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT07128641 |
| Linvoseltamab | DRUG | Phase PHASE1 | Relapsed Refractory Multiple Myeloma (RRMM) | NOT_YET_RECRUITING | NCT07455851 |
| Ezetimibe 10mg | DRUG | Phase PHASE4 | Myocardial Infarction | WITHDRAWN | NCT03750760 |
| Atorvastatin 80mg | DRUG | Phase PHASE4 | Myocardial Infarction | WITHDRAWN | NCT03750760 |
| 89Zr˗DFO˗REGN3504 | DRUG | Phase PHASE1 | Advanced PD-L1 Positive Malignancies | TERMINATED | NCT03746704 |
| Ziv-Aflibercept | BIOLOGICAL | Phase PHASE2 | Uveal Melanoma | TERMINATED | NCT03712904 |
| Stereotactic Body Radiation Therapy | RADIATION | Phase PHASE2 | Uveal Melanoma | TERMINATED | NCT03712904 |
| REGN2477+REGN1033 | DRUG | Phase PHASE2 | Sporadic Inclusion Body Myositis | WITHDRAWN | NCT03710941 |
| Re-irradiation | RADIATION | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| Conventional or hypofractionated | RADIATION | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| cemiplimab (maintenance) | DRUG | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| cemiplimab (monotherapy) | DRUG | Phase PHASE1 | Relapsed Solid Tumor | TERMINATED | NCT03690869 |
| Placebo (blinded) | DRUG | Phase PHASE2 | Eosinophilic Gastritis | COMPLETED | NCT03678545 |
| Dupilumab (blinded) | DRUG | Phase PHASE2 | Eosinophilic Gastritis | COMPLETED | NCT03678545 |
| ISA101b | BIOLOGICAL | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT04646005 |
| Dupilumab | DRUG | Preclinical | Food Allergy | NO_LONGER_AVAILABLE | NCT06631677 |
| REGN5069 | DRUG | Phase PHASE2 | Osteoarthritis of the Knee | TERMINATED | NCT03956550 |
| Topical IOP-lowering drugs | DRUG | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT03639675 |
| Aflibercept (EYLEA, BAY86-5321) | DRUG | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT03639675 |
| REGN4659 | DRUG | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT03580694 |
| Tocilizumab | DRUG | Phase PHASE1 | Recurrent Ovarian Cancer | RECRUITING | NCT03564340 |
| Sarilumab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Ubamatamab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Matching Placebo subcutaneous injection | DRUG | Phase PHASE4 | Saphenous Vein Graft Atherosclerosis | TERMINATED | NCT03542110 |
| Alirocumab 150 MG/ML subcutaneous injection | DRUG | Phase PHASE4 | Saphenous Vein Graft Atherosclerosis | TERMINATED | NCT03542110 |
| Aflibercept Injection | DRUG | Phase PHASE4 | Diabetic Retinopathy | COMPLETED | NCT04708145 |
| REGN4461 | DRUG | Phase PHASE2 | Familial Partial Lipodystrophy | TERMINATED | NCT05088460 |
| Alirocumab 150 MG/ML [Praluent] | DRUG | Phase PHASE3 | Hemodialysis | UNKNOWN | NCT03480568 |
| Anti-PD-1 Monoclonal Antibody REGN2810 | BIOLOGICAL | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Radical Prostatectomy | PROCEDURE | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Stereotactic Body Radiation Therapy (SBRT) | RADIATION | Phase PHASE1 | Stage III Prostate Cancer | WITHDRAWN | NCT03477864 |
| Radiation Therapy | RADIATION | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03438318 |
| Atezolizumab | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT03438318 |
| evinacumab | DRUG | Phase PHASE2 | Hypertriglyceridemia | TERMINATED | NCT04863014 |
| Pexastimogene Devacirepvec (Pexa-Vec) | BIOLOGICAL | Phase PHASE1 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03294083 |
| Fianlimab | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT06787612 |
| Paclitaxel | DRUG | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Pemetrexed | DRUG | Phase PHASE2 | Resectable Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06161441 |
| Gemcitabine | DRUG | Phase PHASE2 | Bladder Cancer | RECRUITING | NCT06571708 |
| Platinum-doublet chemotherapy | OTHER | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Ipilimumab | DRUG | Phase PHASE2 | Advanced Renal Cell Carcinoma (aRCC) | RECRUITING | NCT07188896 |
| Cemiplimab | DRUG | Phase PHASE3 | Cutaneous Squamous Cell Carcinoma (CSCC) | RECRUITING | NCT06585410 |
| Background Lipid Modifying Therapy (LMT) | OTHER | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT03175367 |
| Matching placebo | DRUG | Phase PHASE4 | Asthma | COMPLETED | NCT04203797 |
| Evinacumab | DRUG | Phase PHASE2 | Diabetic Kidney Disease (DKD) | RECRUITING | NCT07271186 |
| REGN3918 | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT04162470 |
| Intravitreal Aflibercept | DRUG | Phase PHASE2 | Diabetic Macular Edema | WITHDRAWN | NCT04588948 |
| optovue angiovue | DEVICE | Phase PHASE4 | Wet Macular Degeneration | COMPLETED | NCT03022292 |
| Aflibercept Ophthalmic | DRUG | Phase PHASE4 | Wet Macular Degeneration | COMPLETED | NCT03022292 |
| REGN3767 | DRUG | Phase PHASE1 | Malignancies | COMPLETED | NCT03005782 |
| Atorvastatin | DRUG | Phase PHASE2 | Nephrotic Syndrome | TERMINATED | NCT03004001 |
| Alirocumab placebo | DRUG | Phase PHASE2 | Nephrotic Syndrome | TERMINATED | NCT03004001 |
| Alirocumab | DRUG | Phase PHASE2 | Hypercholesterolemia | NOT_YET_RECRUITING | NCT07477704 |
| REGN2477 | DRUG | Phase PHASE2 | Fibrodysplasia Ossificans Progressiva | COMPLETED | NCT03188666 |
| Prompt Vitrectomy Plus Panretinal Photocoagulation | PROCEDURE | Phase PHASE2 | Proliferative Diabetic Retinopathy | COMPLETED | NCT02858076 |
| 2-mg Intravitreous Aflibercept Injection | DRUG | Phase PHASE2 | Proliferative Diabetic Retinopathy | COMPLETED | NCT02858076 |
| REGN2222 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02828397 |
| REGN3470-3471-3479 | BIOLOGICAL | Preclinical | Ebola Virus Disease | AVAILABLE | NCT03576690 |
| Rimiducid | DRUG | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT02744287 |
| BPX-601 | BIOLOGICAL | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT02744287 |
| REGN1033 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02943239 |
| Intravitreal aflibercept injection [IAI] | DRUG | Phase PHASE3 | Nonproliferative Diabetic Retinopathy | COMPLETED | NCT02718326 |
| Pembrolizumab | DRUG | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05608291 |
| CMP-001 | DRUG | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT04633278 |
| odronextamab | DRUG | Phase PHASE1 | Relapsed/Refractory Aggressive B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02651662 |
| cemiplimab | DRUG | Phase PHASE1 | Cutaneous Basal Cell Carcinoma | RECRUITING | NCT07251413 |
| Aflibercept (Eylea, BAY86-5321) | DRUG | Preclinical | Wet Age-related Macular Degeneration | COMPLETED | NCT03382587 |
| Prompt Sham | PROCEDURE | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | DRUG | Preclinical | Macular Degeneration | COMPLETED | NCT03411941 |
| Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) | DRUG | Phase PHASE4 | Macular Degeneration | COMPLETED | NCT02581891 |
| aflibercept | DRUG | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT04429503 |
| REGN2810 | DRUG | Preclinical | Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06269133 |
| Fasinumab | DRUG | Phase PHASE2 | Low Back Pain | COMPLETED | NCT02620020 |
| Intravitreal aflibercept injection | DRUG | Phase PHASE4 | Macular Degeneration | COMPLETED | NCT02689518 |
| REGN475 | DRUG | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT02447276 |
| Sham Injection | DRUG | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT02396316 |
| Aflibercept (Eylea, BAY 86-5321) | DRUG | Phase PHASE3 | Glaucoma, Neovascular | COMPLETED | NCT02396316 |
| Suptavumab 30 mg/kg - 2 Doses | DRUG | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Suptavumab 30 mg/kg- 1 Dose | DRUG | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Placebo Matched to Suptavumab | DRUG | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Suptavumab 30 mg/kg | DRUG | Phase PHASE3 | Respiratory Syncytial Virus Infections | COMPLETED | NCT02325791 |
| Aflibercept (EYLEA, BAY-86-5321) | DRUG | Preclinical | Wet Macular Degeneration | COMPLETED | NCT02321241 |
| Focal Laser | PROCEDURE | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02299336 |
| Focal Laser Treatment | PROCEDURE | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02297204 |
| Odronextamab multiple dose levels | DRUG | Phase PHASE1 | Non-Hodgkin Lymphoma | COMPLETED | NCT02290951 |
| REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | DRUG | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02265952 |
| REGN2222(SAR438584) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02121080 |
| Rescue Therapy with PDT, Laser or Intravitreal Steroids | PROCEDURE | Phase PHASE4 | Neovascular Polypoidal Choroidal Vasculopathy | UNKNOWN | NCT02092532 |
| Rescue Intravitreal Aflibercept Injection | DRUG | Phase PHASE4 | Neovascular Polypoidal Choroidal Vasculopathy | UNKNOWN | NCT02092532 |
| REGN2176-3 | DRUG | Phase PHASE2 | Neovascular Age-Related Macular Degeneration | TERMINATED | NCT02418754 |
| REGN910 | DRUG | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT01997164 |
| REGN910-3 | DRUG | Phase PHASE2 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT02713204 |
| REGN1193 | DRUG | Phase PHASE1 | Diabetes Mellitus, Type 2 | TERMINATED | NCT02284425 |
| REGN1908-1909 | DRUG | Phase PHASE3 | Allergic Rhinitis Due to Cat Allergy | TERMINATED | NCT04981717 |
| Deferred aflibercept | DRUG | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Deferred laser | PROCEDURE | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Prompt aflibercept | DRUG | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT02634333 |
| Prompt Laser | PROCEDURE | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01909791 |
| REGN2009 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01893528 |
| Intravitreal aflibercept injection 2.0mg | DRUG | Phase PHASE4 | Polypoidal Choroidal Vasculopathy | COMPLETED | NCT01871376 |
| Aflibercept (2.0 mg) | DRUG | Phase PHASE4 | Macular Edema With Central Retinal Vein Occlusions | COMPLETED | NCT01870427 |
| Placebo: Standard of care only | OTHER | Phase PHASE1 | Corneal Neovascularization | TERMINATED | NCT01868360 |
| Subconjunctival aflibercept | DRUG | Phase PHASE1 | Corneal Neovascularization | TERMINATED | NCT01868360 |
| rilonacept (IL-1 Trap) | DRUG | Phase PHASE1 | Systemic Juvenile Idiopathic Arthritis | COMPLETED | NCT01803321 |
| Ranibizumab (or other DME treatment) | DRUG | Preclinical | Ophthalmology | COMPLETED | NCT01771081 |
| Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321) | DRUG | Preclinical | Macular Degeneration | COMPLETED | NCT01756248 |
| REGN1500 | DRUG | Phase PHASE1 | Metabolic Disorders | COMPLETED | NCT02107872 |
| Cetuximab | DRUG | Phase PHASE2 | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | RECRUITING | NCT06448026 |
| Erlotinib | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01727869 |
| REGN1400 | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01727869 |
| Intravitreal Aflibercept Injection (IAI) | DRUG | Phase PHASE4 | Chorioretinal Vascular Disease | COMPLETED | NCT03767738 |
| 0.3 mg intravitreal ranibizumab | DRUG | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01627249 |
| 1.25 mg intravitreal bevacizumab | DRUG | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01627249 |
| 2.0 mg intravitreal aflibercept | DRUG | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01627249 |
| REGN846 | DRUG | Phase PHASE1 | Pruritus | TERMINATED | NCT01605708 |
| Aflibercept monthly | DRUG | Phase PHASE1 | Radiation Retinopathy | COMPLETED | NCT01579760 |
| Aflibercept every 2 months | DRUG | Phase PHASE1 | Radiation Retinopathy | COMPLETED | NCT01579760 |
| aflibercept 2.0 mg | DRUG | Phase PHASE4 | Diabetic Macular Edema | COMPLETED | NCT02297204 |
| REGN1154 or placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01540539 |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | DRUG | Phase PHASE3 | Branch Retinal Vein Occlusion | COMPLETED | NCT01521559 |
| Aflibercept | DRUG | Phase PHASE1 | Irvine-Gass Syndrome | TERMINATED | NCT03396861 |
| Visudyne | OTHER | Phase PHASE4 | Neovascular Macular Degeneration | COMPLETED | NCT02120950 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | DRUG | Preclinical | Diabetic Retinopathy | COMPLETED | NCT02924311 |
| Allopurinol | DRUG | Phase PHASE3 | Gout | TERMINATED | NCT01459796 |
| allopurinol | DRUG | Phase PHASE4 | Intercritical Gout | COMPLETED | NCT01451645 |
| placebo | DRUG | Phase PHASE2 | Chronic Sinusitis | COMPLETED | NCT04362501 |
| Colchicine (Colcrys®) | DRUG | Phase PHASE4 | Intercritical Gout | COMPLETED | NCT01451645 |
| Macular Laser Photocoagulation | PROCEDURE | Phase PHASE3 | Macular Edema | COMPLETED | NCT01783886 |
| Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | DRUG | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT01363440 |
| Macular Laser Photocoagulation (Control) | PROCEDURE | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01331681 |
| No Drug | PROCEDURE | Phase PHASE3 | Myopia, Pathological | COMPLETED | NCT01249664 |
| VEGF Trap-Eye (BAY86-5321) | BIOLOGICAL | Phase PHASE3 | Macular Edema | COMPLETED | NCT01512966 |
| Sham treatment | OTHER | Phase PHASE3 | Retinal Vein Occlusion | COMPLETED | NCT01012973 |
| Placebo (for REGN475/SAR164877) | DRUG | Phase PHASE2 | Abdominal Pain Upper | TERMINATED | NCT01001923 |
| REGN475/SAR164877 | DRUG | Phase PHASE2 | Abdominal Pain Upper | TERMINATED | NCT01001923 |
| Intravitreal Aflibercept Injection 2mg | DRUG | Phase PHASE4 | Neovascular Age-related Macular Degeneration | UNKNOWN | NCT03468296 |
| Sham | OTHER | Phase PHASE3 | Diabetic Macular Edema | COMPLETED | NCT06422507 |
| VEGF Trap-Eye 2.0mg | BIOLOGICAL | Phase PHASE3 | Macular Edema Secondary to Central Retinal Vein Occlusion | COMPLETED | NCT00943072 |
| Placebo (for Indomethacin) | OTHER | Phase PHASE3 | Acute Gout Flare | COMPLETED | NCT00855920 |
| Indomethacin | DRUG | Phase PHASE3 | Acute Gout Flare | COMPLETED | NCT00855920 |
| Rilonacept 160 mg | DRUG | Phase PHASE3 | Intercritical Gout | COMPLETED | NCT00829829 |
| Rilonacept 80 mg | DRUG | Phase PHASE3 | Intercritical Gout | COMPLETED | NCT00829829 |
| Intravitreal Aflibercept Injection | DRUG | Phase PHASE4 | Cystoid Macular Edema | COMPLETED | NCT02392364 |
| Laser Photocoagulation | PROCEDURE | Phase PHASE2 | Diabetic Macular Edema | COMPLETED | NCT00789477 |
| Placebo | DRUG | Phase PHASE2 | Overweight or Obesity | RECRUITING | NCT07431086 |
| rilonacept 160 mg | DRUG | Phase PHASE3 | Familial Cold Autoinflammatory Syndrome (FCAS) | COMPLETED | NCT00288704 |
| Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | BIOLOGICAL | Phase PHASE3 | Retinal Vein Occlusion | COMPLETED | NCT01012973 |
| Ranibizumab | DRUG | Phase PHASE3 | Macular Degeneration | COMPLETED | NCT00637377 |
| Placebo (for Rilonacept) | OTHER | Phase PHASE3 | Acute Gout Flare | COMPLETED | NCT00855920 |
| Rilonacept | DRUG | Phase EARLY_PHASE1 | Autoimmune Neurosensory Hearing Loss (ANSHL) | UNKNOWN | NCT02828033 |
| VEGF Trap Eye | DRUG | Phase PHASE2 | Macular Degeneration | COMPLETED | NCT00527423 |
| ranibizumab | BIOLOGICAL | Phase PHASE3 | Macular Degeneration | COMPLETED | NCT00509795 |
| VEGF Trap-Eye | DRUG | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT00320814 |
| aflibercept injection (VEGF Trap-Eye, BAY86-5321) | BIOLOGICAL | Phase PHASE3 | Macular Degeneration | COMPLETED | NCT00509795 |
| VEGF Trap | BIOLOGICAL | Phase PHASE1 | Neovascular Age Related Macular Degeneration | COMPLETED | NCT00383370 |
| ziv-aflibercept | BIOLOGICAL | Phase PHASE1 | Cancer | COMPLETED | NCT00083213 |
Total products: 4326